



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 63/00, 65/00, C12N 7/00, 7/01, 5/00, 5/02, 15/00, 15/09, 15/63, 15/70, 15/74, C07H 19/00, 21/00, 21/02, 21/04		A1	(11) International Publication Number: WO 97/20468
			(43) International Publication Date: 12 June 1997 (12.06.97)
(21) International Application Number: PCT/US96/19512		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 9 December 1996 (09.12.96)		Published <i>With international search report.</i>	
(30) Priority Data: 08/569,853 8 December 1995 (08.12.95) US			
(71) Applicant (for all designated States except US): ST. LOUIS UNIVERSITY [US/US]; 3635 Vista Avenue, St. Louis, MO 63110-0250 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BELSHE, Robert, B. [US/US]; 338 Oakwood Avenue, St. Louis, MO 63119 (US). RAY, Ranjit [IN/US]; 1612 Holly Drive, St. Louis, MO 63119 (US).			
(74) Agents: STONE, Paul, A. et al.; Senniger, Powers, Leavitt and Roedel, 16th floor, One Metropolitan Square, St. Louis, MO 63102 (US).			
(54) Title: LIVE ATTENUATED VACCINES BASED ON cp45 HPIV-3 STRAIN AND METHOD TO ENSURE ATTENUATION IN SUCH VACCINES			
(57) Abstract			
<p>The present invention is based upon correlation of two attenuating lesions of the cp45 strain to specific defects in the genome of cp45. Specifically, a significant level of attenuation of cp45, resulting from its temperature-sensitive and cold-adapted phenotypes is associated with mutation of the L gene of cp45. A second mutation in the gene coding for hemagglutinin-neuraminidase (HN) in the cp45 strain has also been found to be another attenuating mutation. The correlation of these two attenuating lesions of cp45 to specific genes enables several practical applications. It is now possible to create attenuated vaccines directed at other wild-type HPIV-3 viruses and other viruses other than HPIV-3 by incorporating the mutated L and/or HN genes of cp45 into a target virus genome or alternatively, expressing surface antigen genes from other viruses in cp45.</p>			
Ref. #3 SLU 4538 R. Belshe et al. 09/785, 764			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

LIVE ATTENUATED VACCINES BASED ON cp45 HPIV-3 STRAIN
AND METHOD TO ENSURE ATTENUATION IN SUCH VACCINES

5 Funding for research supporting this invention was
provided, in part, by the U.S. Department of Health and
Human Services. The U.S. Government may have certain
rights in this invention.

BACKGROUND OF THE INVENTION

10 The present invention relates to enveloped,
negative-sense, single-stranded RNA viruses and to the
use of such viruses as live attenuated vaccines.
Specifically, the invention relates to new human vaccines
for enveloped viruses such as parainfluenza, respiratory
syncytial virus, measles and influenza viruses, among
15 others. The invention also relates to a method for
screening such vaccines to ensure attenuation prior to
their administration and to check the stability of the
attenuated strain after administration.

20 A number of viruses may cause severe infections in
humans and animals. For example, respiratory syncytial
virus (RSV) and parainfluenza virus are two of the
leading causes of severe upper and/or lower respiratory
tract disease in neonates and young infants. Other
viruses, such as influenza virus, measles virus and human
25 immunodeficiency virus, are also of significant concern.

30 A variety of vaccines have been developed over the
years to prevent viral infections in animals and humans.
Two principle types of vaccines have been used: killed
viruses and attenuated live virus. A killed virus is
typically inactivated by chemical or physical treatment,
but is generally less effective in stimulating a lasting
immune response than an attenuated live virus.
Attenuated live viruses are typically more effective, but
may revert back to their virulent state while in the

body. The time and cost involved in developing either killed or live vaccines is significant.

Live, attenuated vaccines may be obtained directly from progeny viruses isolated from infected animals. For example, U.S. Patent No. 3,927,209 to Straub discloses a parainfluenza type-3 vaccine isolated as a virus strain from a bovine respiratory tract. Live attenuated vaccines may also be obtained by repeatedly cold passaging a wild-type strain through suitable cultures until the virus has lost its original pathogenic properties. For example, cp45, a cold-adapted, temperature sensitive strain was obtained by passing the wild-type virus (JS strain) of HPIV-3 45 times at reduced temperatures. (Belshe and Hissom, 1982). The temperature sensitive cp45 strain is currently under evaluation for use as a candidate vaccine in humans. (Karron et al. 1995; Hall et al. 1993; Belshe et al. 1992; Clements et al. 1991; Crookshanks-Newman and Belshe 1986). Recent evaluation in children has revealed the cp45 strain to be highly attenuated and effective in stimulating immunogenic response. (Karron et al. 1995; Belshe et al. 1992).

Attenuation in a particular vaccine strain is commonly evaluated with respect to three phenotypes of the strain: cold adaptation, temperature sensitivity and plaque size or yield in tissue culture. Cold adaptation relates to the ability of the virus to grow at 20 °C and the temperature sensitivity relates to whether such growth is inhibited at temperatures of around 40 °C. Plaque titers are an assay for quantitatively evaluating the extent of virus growth, and are commonly used to evaluate the extent of cold-adaptive and/or temperature sensitive phenotypes. Other methods for determining whether an vaccine is attenuated involve administering the vaccine to primates. For example, new polio vaccine

lots are typically administered to monkeys before being approved for sale by the FDA.

A continuing need exists for developing new vaccines. The prior art methods of developing live

5 attenuated vaccines by cold passaging, while often effective, are not predictable as to their success, and are necessarily limited to application against a single virus. A need also exists for alternative methods to determine whether a virus is sufficiently attenuated.

10 Characterization of cold adaptive and temperature sensitive phenotypes are not definitive. Administration of vaccines to test animals are likewise not definitive, and are inefficient.

SUMMARY OF THE INVENTION

15 It is therefore an object of the invention to develop vaccines which are suitable for use against a variety of human and animal viruses, and particularly, against viruses such as human parainfluenza viruses types 1, 2 or 3 and RSV. It is likewise an object to provide 20 more efficient and reproducible methods for determining whether a virus strain is attenuated.

Briefly, therefore, the present invention is directed to enveloped, negative-sense, single-stranded RNA hybrid viruses, and further, to live, attenuated 25 human and/or animal vaccines comprising the hybrid viruses in combination with a pharmaceutically acceptable carrier. Vaccines comprising the hybrid virus can be directed against a variety of target viruses, including human parainfluenza type-3 (HPIV-3) viruses and viruses 30 other than HPIV-3.

A hybrid virus suitable for use in a vaccine directed against non-HPIV-3 target virus has a chimeric viral genome comprising the following genes operatively linked for expression in combination with any other genes 35 necessary to form a viable virus: (i) a nucleic acid

sequence which encodes one or more surface antigens of a target virus and (ii) a nucleic acid sequence which encodes a variant large protein, L. The target virus is, in this case, not a HPIV-3 virus and the target virus has surface antigens or proteins which are antigenically different from surface antigens of cp45. The variant L protein is a HPIV-3 L protein having an amino acid sequence which has at least about a 90% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein. Additionally, the variant L protein has at least one variation in amino acid sequence relative to its wild-type HPIV-3 L protein and has polymerase activity which is less than the polymerase activity normally associated with the target virus at a temperature of about 39°C.

The genome of the immediately aforementioned hybrid virus can comprise, operatively linked for expression: (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of cp45; (ii) a nucleic acid sequence which encodes the nucleocapsid protein, NP, of cp45; (iii) a nucleic acid sequence which encodes the phosphoprotein, P[+C], of cp45; (iv) a nucleic acid sequence which encodes the matrix protein, M, of cp45; (v) a nucleic acid sequence which encodes at least one surface antigen of a target virus selected from the group consisting of HPIV-1, HPIV-2 and RSV; and (vi) a nucleic acid sequence which encodes a variant large protein, L, having RNA-polymerase activity which is less than the polymerase activity normally associated with the target virus at a temperature of about 39°C. The variant L protein has, in this case, at least about a 99.8% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and has at least two substitutions in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein,

the substitutions being His for Tyr at residue 942 and Phe for Leu at residue 992.

Another hybrid virus suitable for use in a vaccine directed against non-HPIV-3 target virus has a chimeric 5 viral genome comprising genes operatively linked for expression. These genes include, in combination with other genes necessary to form a viable virus, a nucleic acid sequence which encodes (i) at least one surface antigen of a non-HPIV-3 target virus which is 10 antigenically different from surface antigens of cp45 and (ii) a portion of the cp45 HN protein. The encoded portion has a neuraminidase activity and includes an amino acid sequence which is the same as the amino acid sequence from residue 160 to residue 385 of the HN 15 protein of cp45. The invention is further directed to live, attenuated vaccines suitable for use against the target virus. The vaccine comprises the immediately aforementioned hybrid virus and a pharmaceutically acceptable carrier. The invention is directed, moreover, 20 to a plasmid vector having a genome which includes the genome of the hybrid virus and to methods for producing the hybrid virus.

The invention is further directed to an enveloped, negative-sense, single-stranded RNA hybrid virus suitable 25 for use in a vaccine directed against HPIV-3 viruses. One such hybrid virus has a genome which comprises the following genes operatively linked for expression in combination with any other genes necessary to form a viable virus: (i) a nucleic acid sequence which is the 30 same as the nucleic acid sequence of the 3' leader region of a wild-type HPIV-3 target virus or which encodes at least one protein selected from the group consisting of the matrix protein, M, of the target virus, the fusion protein, F, of the target virus and the hemagglutinin-neuraminidase protein, HN, of the target virus, and (ii) 35 a nucleic acid sequence which encodes a variant HPIV-3

large protein, L. The variant L protein has an amino acid sequence which has at least one variation in amino acid sequence relative to the L protein of the target virus, and has RNA-polymerase activity which is less than 5 the RNA-polymerase activity normally associated with the L protein of the target virus at a temperature of about 39°C.

Another hybrid virus suitable in the same regard is an enveloped, negative-sense, single-stranded RNA hybrid 10 virus having a genome comprising the following genes operatively linked for expression in combination with any other genes necessary to form a viable virus: (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of a wild-type 15 HPIV-3 target virus or which encodes at least one protein selected from the group consisting of the matrix protein, M, of the target virus, the fusion protein, F, of the target virus and the large protein, L, of the target virus, and (ii) a nucleic acid sequence which encodes a 20 variant hemagglutinin-neuraminidase protein, HN. The variant HN protein has an amino acid sequence which has at least about a 90% sequence identity with the amino acid sequence of the HN protein of wild-type HPIV-3 (JS) virus and which has at least one variation in amino acid 25 sequence relative to the HN protein of the target virus. The variant HN protein also has at least one variation in amino acid sequence relative to the HN protein of the HPIV-3 (JS) virus. The variation relative to the HN protein of HPIV-3 (JS) is at or within about five amino 30 acid residues of residue 384 of the JS HN protein. The variant HN protein has neuraminidase activity which is less than the neuraminidase activity normally associated with the HN protein of the target virus.

The invention is also directed to a plasmid vector 35 comprising a positive or negative sense genome having the genes for any of the aforementioned hybrid viruses

operatively linked for expression in combination with other genes necessary to form a viable plasmid. For example, the plasmid genome of one plasmid vector of the invention includes: (i) a nucleic acid sequence which encodes the surface antigens of a target virus and (ii) a nucleic acid sequence which encodes a variant large protein, L. The target virus surface antigens are antigenically different from surface antigens of cp45. The variant L protein has an amino acid sequence which has at least about a 90% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and which has at least one variation in amino acid sequence relative to the L protein of its wild-type L protein and relative to wild-type HPIV-3 (JS). The variant L protein has an RNA-polymerase activity which is less than the polymerase activity normally associated with the target virus at a temperature of about 39°C.

The invention is, moreover, directed to a host cell transfected with a plasmid vector of the invention.

20 The invention is also directed to methods for
producing enveloped, negative-sense, single-stranded RNA
viruses. A host cell is transfected with a plasmid
vector of the invention which includes the genome of one
of the aforementioned hybrid viruses (e.g. such as the
25 plasmid vector described in detail above). The host cell
is then cotransfected with plasmid vectors that express
wild-type HPIV-3 NP, P and L proteins. The transfected
host cell is incubated to produce a hybrid virus. The
hybrid virus is then isolated in a pharmaceutically
30 acceptable carrier or medium.

The invention is furthermore directed to a method for determining whether a HPIV-3 or a cp45-hybrid virus is attenuated. The method comprises confirming the presence of at least one variation in the genome of the virus relative to the genome of wild-type HPIV-3. The

variation is in the region of the genome which encodes the L protein or the HN protein.

The present invention is also directed to a method for determining whether a virus has a temperature sensitive phenotype. A sample of HPIV-3 or a cp45-hybrid virus is obtained and a first plaque assay is performed. A host cell is transfected with a plasmid vector that expresses wild-type HPIV-3 L protein and infected with the virus. After incubating, a second plaque assay is performed and compared to the first plaque assay.

The invention offers new opportunities for producing live vaccines which can be used in conjunction with a variety of viruses. Because vaccines of the present invention incorporate, in a preferred embodiment, the cp45 genes which give rise to the attenuating lesions exhibited by cp45, the vaccines disclosed and claimed herein are expected to be attenuated during use in humans or animals. Furthermore, the invention provides a direct and efficient method for determining temperature sensitive phenotype and attenuation in HPIV-3 viruses and in cp45 hybrid viruses.

Other features and objects of the present invention will be in part apparent to those skilled in the art and in part pointed out hereinafter.

25

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of the HPIV-3 viral genome, shown vertically 5' (top) to 3' (bottom) in its cDNA sense. The genomic regions are labeled to correspond to the leader region and the regions of the genome which encode the nucleocapsid protein, NP, the phosphoprotein, P(+C), the matrix protein, M, the fusion protein, F, the hemagglutinin-neuraminidase protein, HN and the large protein, L. The position number for nucleotide changes in the leader region correspond to their position in relation to the genome, whereas all

other position numbers refer to the position of nucleotide changes within the individual gene.

FIGS. 2A and 2B are photos depicting the results of Southern hybridization or southern blot analysis, 5 comparing mRNA levels of P protein gene between cp45 and wild-type HPIV-3 (JS). Fig. 2A shows cDNA after 15 cycles of PCR amplification from wild-type HPIV-3 (lane 1), cp45 (lane 2) and plasmid DNA containing the P gene (lane 3). The size of the amplified DNA, shown by an 10 arrow on the right, was calculated on the basis of migration of Φ X174/HaeIII-digested DNA marker (data not shown). Fig 2B depicts the results of a slot blot hybridization analysis using phosphorimaging analysis using the Molecular Dynamics PhosphorImager. As 15 indicated thereon, the left lane is for cp45 and the right lane for the wild-type HPIV-3 (JS) strain.

FIGS. 3A and 3B are photos depicting the results of a pulse-chase experiment, demonstrating the kinetics of viral protein synthesis. Cells infected with the wild-type HPIV-3 (JS) or cp45 were grown at 39.5 °C for 24 20 hours and pulsed with 35 S-protein label for 1 hour. Fig. 3A shows cell lysates immunoprecipitated with Rabbit anti-HPIV-3 at the time points indicated under each lane (0, 1, 2, 3 and 4 hours) for both wild-type JS strain (left-most five lanes) and cp45 (right-most five lanes). Fig. 3B shows cell lysates immunoprecipitated with pooled 25 monoclonal antibodies to HN and NP of wild-type HPIV-3 at the time points indicated under each lane (0, 1, 2 and 3 hours) for both wild-type JS strain (left-most four lanes) and cp45 (right-most four lanes).

FIGS. 4A and 4B are bar graphs showing the reactivities of cp45 and wild-type HPIV-3 with monoclonal antibodies to HN protein (Fig. 4A) and to F protein (Fig. 4B, as determined by ELISA. Results are presented as the 35 mean optical densities (O.D.) from three different experiments at a particular dilution of the antibodies

(1:1800). The monoclonal antibodies 7.12.3, 9.1.6.2, 7.14.2, 5.4.8 and 9.4.3.6 define antigenic sites of HPIV-3 (strain 47885). Monoclonal antibodies 170/7, 77/5, c/267, c/215, b/108, a/640 and a/591 were provided 5 by Judy Beeler (World Health Organization Reagent Bank).

FIGS. 5A and 5B are photos of gels depicting the immunoprecipitation of HPIV-3 proteins expressed by the vaccinia virus T7 system with rabbit antiserum and with monoclonal antibodies. HeLa-T4 cells were transfected 10 with plasmids containing the HPIV-3 L, P or NP gene. About 20 hours posttransfection, the cells were radiolabelled with [³⁵S]-methionine- [³⁵S]-cysteine at 37 °C for 1 hour. The HPIV-3 proteins from cell lysates were immunoprecipitated with a rabbit antiserum to HPIV-3 or a 15 monoclonal antibody to NP and analyzed by SDS-PAGE. The labeled proteins were electrophoresed on SDS-7.5% (Fig. 5A) and SDS-10% (Fig. 5B) in the presence of the reducing agent 2-mercaptoethanol. The lanes in Fig. 5A correspond to: vector DNA-transfected cell lysates 20 immunoprecipitated with rabbit antiserum to HPIV-3 (lane 1); P-gene-transfected cell lysates immunoprecipitated with rabbit antiserum to HPIV-3 (lane 2); and L-gene-transfected cell lysates immunoprecipitated with rabbit antiserum to HPIV-3 (lane 3). The lanes in Fig. 5B 25 correspond to: vector DNA-transfected cell lysates immunoprecipitated with rabbit antiserum to HPIV-3 (lane 1); L-gene-transfected cell lysates immunoprecipitated with rabbit antiserum to HPIV-3 (lane 2); NP-gene-transfected cell lysates immunoprecipitated with a 30 specific monoclonal antibody (lane 3). Positions of molecular weight markers are shown on the left in kilodaltons.

FIGS. 6A through 6D are photos depicting the indirect immunofluorescence staining of cells transiently 35 expressing HPIV-3 NP protein (Fig. 6A), P protein (Fig. 6B) or L protein (Fig. 6C), and shows their growth

relative to a negative control (Fig. 6D). Cells expressing HPIV-3 NP, P and L proteins and control cells transfected with vector DNA's were fixed and reacted with a primary anti-HPIV-3 antibody and a secondary mouse 5 anti-rabbit immunoglobulin G-fluorescein isothiocyanate conjugate for immunofluorescence.

FIGS. 7A and 7B are graphs showing the growth characteristics of cp45 (Fig. 7A) and HPIV-3 (JS) (Fig. 7B) in a L-132 cell culture at 32°C with or without the 10 addition of exogenous bacterial neuraminidase to the culture medium. The bars indicate the standard errors of three independent experiments.

FIGS. 8A through 8D are photos showing the cytopathic effect developed by cells infected with cp45 15 (FIG. 8A) and HPIV-3 (JS) (FIG 8B) after growth in culture without exogenous neuraminidase and of cells infected with cp45 (FIG. 8C) and HPIV-3 (JS) (FIG. 8D) after growth in the presence of exogenous neuraminidase. Cells were infected at a multiplicity of infection of 20 0.01 and incubated at 32 °C for 36 hours either with or without exogenous neuraminidase.

FIGS. 9A through 9D are photos based on 25 immunofluorescent methods which show the distribution of HN glycoprotein of cp45 (FIG. 9A) and HPIV-3 (JS) (FIG. 9B) in tissue culture cells after growth without exogenous neuraminidase, and of cp45 (FIG. 9C) and HPIV-3 (JS) (FIG. 9D) in tissue culture cells after growth in the presence of exogenous neuraminidase.

FIGS. 10A and 10B are graphs showing the variation 30 in neuraminidase activity of cp45 (FIG. 10A) and HPIV-3 (JS) (FIG. 10B) for infected cell cultures incubated at various Ph. The neuraminidase activity assays were performed using fetuin (open circle) or neuraminolactose (closed circle) as substrates.

35 FIGS. 11A and 11B are graphs showing the variation in neuraminidase activity with time in kinetic studies in

which cp45 (open circles) and wild-type JS strains (closed circles) were assayed using a neuraminolactose substrate having either a 2→3 linkage (FIG. 11A) or a 2→6 linkage (FIG. 11B).

5 FIGS 12A and 12B are bar graphs showing the results of neuraminidase activity inhibition studies in which cp45 (shaded areas) and HPIV-3 (JS) (unshaded areas) were assayed with a monospecific rabbit antiserum to affinity purified HPIV-3 HN glycoprotein and three monoclonal 10 antibodies to the HN glycoprotein, 2-14-1, 13-9-6-2 and 170/8 using either fetuin (FIG. 12A) or neuraminolactose (FIG. 12B) as substrates.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "HPIV-3" means human 15 parainfluenza-type 3 and includes all HPIV-3 strains, including all wild-type HPIV-3 strains and attenuated strains such as cp45. The term "wild-type HPIV-3" refers to wild-type strains and excludes attenuated mutant strains. "HPIV-3 (JS)" or "JS strain" refers to the 20 wild-type JS strain of HPIV-3. (Belshe and Hissom 1982). The term "cp45" refers to the attenuated, temperature-sensitive and cold-adapted cp45 strain of wild-type HPIV-3 (JS), deposited with the American Type Culture Collection (ATCC) (Rockville, MD), Accession No. 25 _____. The contents of each of the references cited herein are hereby incorporated by reference in their entirety.

The present invention is based upon correlation of two attenuating lesions of the cp45 strain to specific 30 genetic defects in the viral genome of cp45. Specifically, it is now understood that a significant level of attenuation of cp45 giving rise to its temperature-sensitive and cold-adapted phenotypes is directly associated with mutation of the large, or L, 35 gene of cp45 relative to the corresponding gene in the

wild-type JS strain. Moreover, it is further understood that a second attenuating lesion exists independently of the temperature-sensitive lesion, and is directly associated with mutation of the hemagglutinin-neuraminidase gene, or [HN] gene, of cp45 relative to the corresponding gene in the wild-type HPIV-3 (JS) strain. The correlation of these two attenuating lesions of cp45 to specific genes enables several practical applications. It is now possible to create vaccines directed at other wild-type HPIV-3 viruses and, additionally, vaccines directed at target viruses other than HPIV-3 using genetic engineering techniques. For example, the mutated L and/or HN genes of cp45 can be incorporated into the viral genome of a target virus. Alternatively, the genes of the target virus which encode its surface antigens can be incorporated into the viral genome of cp45. Moreover, it is possible to determine whether an HPIV-3 strain or a hybrid virus strain made by the methods disclosed herein is attenuated by confirming the presence or absence of mutations in its L and/or HN genes. A verification of attenuation is desirable before administration as a check of new vaccine lots and also after such administration to ensure the stability (i.e., non-reversion) of the vaccine virus. The hybrid viruses described herein are also useful for studying the effect of and role of mutant L and HN genes and the corresponding variant L and HN proteins on the processes of viral infection, reproduction, and spread in cells.

HPIV-3 is an enveloped, negative-sense, single-stranded RNA virus. Its viral genome encodes at least six structural proteins, including, in succession from the 3' end: [3'-NP-P(+C)-M-F-HN-L-5'], wherein 3' refers to the 3' leader region of the genome and wherein NP, P(+C), M, F, HN, and L refer to the regions of the genome which encode the nucleocapsid protein, the phosphoprotein, the matrix protein, the fusion protein,

the hemagglutinin-neuraminidase protein, and the large protein, respectively. (Spriggs and Collins 1986; Storey et al 1984). Relatively short, non-coding intergenic regions separate each of the regions encoding functional proteins.

The nucleocapsid protein, NP, is the most abundant structural protein. It encapsidates the genomic RNA and is believed to maintain the structural integrity and template function of the genome. The L protein functions as the RNA-dependent RNA polymerase, and the P protein functions as an auxiliary regulatory protein which supports the function of L. The P(C+) gene also contains a (C+) reading frame. The matrix, fusion, and hemagglutinin-neuraminidase proteins, M, F and HN, respectively, collectively form the lipid envelope which surrounds the nucleocapsid core. M forms the structural internal portion of the envelope, while F and HN are surface glycoproteins. The hemagglutinin or H portion of the HN protein and the F protein are responsible for attachment onto and penetration into a host cell by HPIV-3, while the neuraminidase or N portion of the HN protein is responsible for release of the progeny viruses from the host cell after replication.

During reproduction of paramyxoviruses such as HPIV-3 in the cytoplasm of infected cells, the nucleocapsid (RNA-NP) serves as a template for transcription by the viral RNA polymerase, L. L and P proteins are both associated with the RNA-NP core, and during primary transcription, the L-P complex interacts with the nucleocapsid core to transcribe the genomic RNA into individual mRNAs which code for viral proteins. In addition, during replication in an infected cell, NP may form a soluble complex with P. This complex is thought to interact with transcribing nucleocapsid complexes to switch from primary transcription to replication of the viral RNA.

The complete nucleic acid sequences of the wild-type HPIV-3 (JS) genome and of the temperature sensitive cp45 genome are known and have been compared. (Stokes et al. 1993; Galinski et al. 1988; Galinski et al. 1986; 5 Galinski et al. 1986'; Spriggs and Collins 1986; Spriggs and Collins 1986'; Storey et al. 1984). At least 18 nucleotide differences exist between wild-type HPIV-3 (JS) genome and the cp45 genome, as shown in Fig. 1. However, nine of these 18 nucleotide changes are found in 10 non-attenuated strains or do not result in amino acid changes in the proteins which they encode. Two of the remaining changes are in the non-coding 3' leader region, but may be important for regulation. Hence, at least seven remaining nucleotide differences between the cp45 15 genome and the wild-type genome are known to result in amino acid sequence changes in four variant proteins: M, F, HN and L. The changes in amino acid sequences of the variant cp45 proteins relative to the corresponding wild-type JS proteins include: in the M gene, substituting threonine (Thr) for proline (Pro) at residue 199; in the F gene, substituting valine (Val) for isoleucine (Ile) at residue 420 and threonine (Thr) for alanine (Ala) at residue 450; in the HN gene, substituting alanine for valine at residue 384; and in the L gene, substituting 20 histidine (His) for tyrosine (Tyr) at residue 942, phenylalanine (Phe) for leucine (Leu) at residue 992 and isoleucine (Ile) for threonine (Thr) at residue 1558.

The variations in the region of the wild-type HPIV-3 (JS) genome which encodes the L protein are now 25 understood to directly correlate to the temperature sensitive phenotype of the cp45 strain. That is, the temperature sensitive phenotype of the cp45 strain of HPIV 3 (JS) is caused by a mutation in the large, or L, gene of cp45 relative to the corresponding gene in the wild-type JS strain. The L gene encodes the RNA-dependent RNA polymerase of the HPIV-3 virus. The gene 30

product of the mutant L gene, referred to herein as a variant L protein, has a decreased polymerase activity relative to that of the wild-type JS strain at higher, non-permissive temperatures. Such decreased polymerase 5 activity results in reduced transcription of the viral RNA and reduced synthesis of viral proteins. Some reduction in transcriptional activity is observed beginning at about 37°C, and a marked reduction occurs at or above about 38°C. Hence, the non-permissive 10 temperatures for cp45 are considered to be temperatures greater than about 37°C, and generally ranging from about 37°C to about 40°C. Without being bound by theory, it is believed that higher temperatures and, in addition, Ph changes developed in certain cellular compartments due to 15 such higher temperatures cause conformational changes in the mutant RNA-dependent RNA polymerase. Specifically, the His and Phe substitutions in the L protein, at residues 942 and 992, respectively, are believed to be important contributors to the presence of the temperature 20 sensitive phenotype. Histidine-phenylalanine interactions are Ph dependent, and intracellular Ph changes are affected by temperature. A shift to the higher non-permissive temperatures and a corresponding change in Ph results in histidine-phenylalanine 25 interactions which cause conformational changes in the RNA dependent RNA polymerase (L protein). Such conformational changes, in turn, result in a decreased activity of the polymerase and a corresponding decrease in transcription and replication. Because the observed 30 decrease in polymerase activity is not observed at lower, permissive temperatures, a virus having the variant L protein will be attenuated and will exhibit the characteristic temperature sensitive phenotype, thereby making it suitable for use as a vaccine. The wild-type 35 RNA-dependent RNA polymerase does not appear to undergo such temperature sensitive conformational changes.

The temperature-dependent replication of the cp45 strain clearly contributes to the observed attenuation in the cp45 vaccine. As shown in Table 1, replication of the temperature sensitive cp45 strain is reduced by a 5 factor of about 10^6 as compared to replication of the wild-type ("WT") JS strain. (Example 1). cp45 showed some replication upon shifting the incubation temperature from 39.5°C to 32°C after 24 hours at the higher temperature, and hence demonstrated the characteristic 10 temperature-sensitive phenotype. The poor transcriptional activity of the cp45 virus strain results in markedly reduced mRNA synthesis at 39.5°C, and as a result, protein synthesis and virus growth are significantly affected. (Example 1).

15 **TABLE 1** Comparison of yields of cp45 and parent wild-type (WT) viruses in a temperature-shift experiment

Virus Strain	Incubation Temp (°C)	Virus yield ^a
cp45	32	2.9×10^7
WT	32	1×10^7
cp45	39.5	1.2×10^1
WT	39.5	8×10^6
cp45	39.5 → 32 ^b	2×10^3
WT	39.5 → 32 ^b	1.5×10^7

^aVirus yields in L-132 cells, infected at similar multiplicities of infection, are expressed after 48 h of incubation.

^bTemperature shift.

30 The temperature dependent activity of the cp45 RNA-dependent RNA polymerase (L protein) and the corresponding reduced transcription of cp45 at non-permissive temperatures (about 40°C) is associated with variations in the region of the viral genome which 35 encodes the L protein. Whereas a cell infected with cp45

alone does not replicate significantly, cells which were co-transfected with cp45 and a recombinant DNA vector which expressed wild-type L protein showed significant levels of replication. (Examples 4 and 5). Table 2

5 reports virus replication yields of complementation plaque assays done on L-132 cells. Briefly, CV-1 cells were cotransfected with plasmid DNA (pRSV-T) encoding the SV40 large T antigen and the recombinant plasmid DNAs (L, P, and/or NP). The CV-1 cells were then infected with

10 cp45 virus at 20 hours post-transfection and incubated at 39.5°C for 28 hours. As shown in Table 2, when the temperature sensitive cp45 strain is complemented by non-mutant wild-type L protein in a complementation assay, the level of replication, as measured by plaque assay

15 methods, increased by a factor of more than 100 relative to the uncomplemented cp45. In contrast, complementation of the cp45 strain with wild-type P protein or with wild-type NP protein had no effect on replication. Cells cotransfected with cp45 and with wild-type L and P

20 proteins, or with wild-type L, P and NP proteins, showed similar increases in yield over cells cotransfected with cp45 and wild-type L protein alone, thereby indicating the key role of the L protein.

25 **TABLE 2** Complementation assay for recovery of cp45 virus at the nonpermissive temperature (39.5°C)

Gene(s) used in complementation	Virus recovery titer (PFU/ml of culture medium) at 32°C
None.....	<1.0
30 L, P, and NP.....	2.3 x 10 ³
L and P.....	1.9 x 10 ²
L.....	3.3 x 10 ²
P.....	<1.0
NP.....	<1.0

35 Importantly, cp45 progeny virus produced from co-transfected cells in which wild-type L protein was used

to complement the cp45 strain at non-permissive temperatures retained the temperature sensitive phenotype of the parent cp45 strain. (Example 6). Further, the L protein complementation of cp45 is heterotypically 5 exclusive. (Example 6). Hence, the recovery of cp45 replication at higher, non-permissive temperatures by complementing the cp45 strain with wild-type L protein demonstrates that the variant L protein (RNA-dependent RNA polymerase) is responsible for the temperature 10 sensitive phenotype of cp45. While other attenuating lesions also contribute to attenuation of cp45, the contribution of the variant L protein is particularly significant.

A second attenuating lesion of the cp45 strain has 15 been linked to a mutation in the hemagglutinin-neuraminidase gene, or [HN] gene, of cp45 relative to the corresponding gene in the wild-type HPIV-3 (JS) strain. The HN gene encodes a protein having both hemagglutinin activity and neuraminidase activity. The gene product of 20 the mutant HN gene, referred to herein as a variant HN protein, has decreased neuraminidase activity relative to the HN protein of the wild-type (JS) strain. There is a substitution of alanine for valine at amino acid residue 384 of the HN protein. The decreased neuraminidase 25 activity, which may be due to a conformational change attributable to this amino acid substitution, inhibits the release of progeny virus from infected host cells, thereby slowing and reducing the extent to which the virus spreads to and replicates in other cells.

30 Several experiments demonstrate that reduced neuraminidase activity is directly associated with the variant HN protein and is independent of and complementary to the temperature sensitive lesion associated with the variant L protein. Growth 35 characteristics of cp45 and wild-type (JS) virus strains at 32°C were determined in cultures in which exogenous

neuraminidase was either absent or present. (Example 7). As shown in Figure 7A, cp45 virus titers taken after about 50 hours of incubation in a culture medium lacking exogenous neuraminidase were about five to fifteen times 5 lower than corresponding titers taken after incubation in a culture medium containing exogenous neuraminidase. In contrast, wild-type JS virus titers were virtually identical after about 25 hours regardless of whether or not exogenous neuraminidase was present in the culture 10 medium. (Fig. 7B).

Moreover, L-132 cells infected with cp45 at a low multiplicity of infection and grown at 32 °C exhibited localized cell fusion with characteristic multinucleated giant cell or syncytia formation. (Fig. 8A; Example 8). 15 Consistently, the distribution of the variant HN protein expressed in L-132 cells infected with cp45 at 33°C was restricted to localized areas. (Fig. 9A; Example 9). However, the addition of exogenous neuraminidase to the culture medium in experiments which paralleled each of 20 the two immediately aforementioned experiments resulted in a dramatic reduction in both the degree of localized cell fusion (Fig. 8C) and the extent of restricted and localized distribution of the variant HN protein (Fig. 9C). The cytopathic effect observed in cp45 infected 25 cells incubated in the presence of exogenous neuraminidase was similar to that observed in JS infected cells, which exhibited significantly less localized cell fusion regardless of whether they were incubated in the absence of (Fig. 8B) or presence of (Fig. 8D) exogenous 30 neuraminidase. Uniform and similar distribution of the wild-type JS HN glycoprotein was observed in the absence of (Fig. 9B) or presence of (Fig. 9D) exogenous neuraminidase. The absence of fusion promotion activity following addition of bacterial neuraminidase in the 35 culture medium indicates that fusion of cp45 is associated with its neuraminidase activity. The

restricted distribution of the variant HN protein in the culture media and the extensive localized cell fusion exhibited by the virus having the variant HN protein indicates that the release of viral progeny from the 5 infected cell is reduced relative to cells infected with the wild-type JS strain, and that multi-cell replication of the virus is inhibited by the variant cp45 HN protein.

Neuraminidase activity studies suggest a conformational change in the cp45 variant HN protein 10 relative to the HN protein of the wild-type JS strain. Referring to Table 3, a decrease in neuraminidase activity of the cp45 strain relative to the JS strain is exhibited at both the non-permissive (39.5 °C) and permissive (32°C) temperatures. (Example 2). At the 15 higher, non-permissive temperature, the cp45 neuraminidase activity differed from that of the JS strain regardless of whether fetuin or neuraminlactose was used as the assay substrate. At the lower, permissive temperature however, a difference in 20 neuraminidase activity for the two strains was observed only in assays using fetuin as a substrate. No difference was observed at the permissive temperature between the activity of the cp45 and JS strains when the assay used the relatively smaller neuraminlactose 25 substrate. The observed substrate dependency suggests that the tertiary structure of the neuraminidase-activity-conferring portion of the HN protein for cp45 appears to be different from that of the JS strain.

TABLE 3 Comparison of neuraminidase activities of cp45 and parent wild-type (WT) viruses

Virus strain	Incubation temp (°C)	HA ^a units used	Neuraminidase activity with ^b :	
			Fetuin	Neuramin- lactose
WT	39.5	512	0.24	3.60
	39.5	512	0.03	0.83
cp45	32	2,048	1.11	2.30
	32	2,048	0.67	2.30

^aHA = hemagglutinin activity.

^bResults are presented as optical density values at 549nm.

Additional differences in enzymatic properties were observed in further neuraminidase studies. The pH optima of neuraminidase activity in cp45 and JS strains were compared using neuraminidase activity assays with either 15 fetuin or neuraminlactose as the assay substrate.

(Example 10). As seen by comparing the data in Figures 10A and 10B, when the neuraminidase activity is assayed with the smaller substrate, neuraminlactose, the optimal pH for the cp45 and JS strains was the same --- about 20 5.5. However, when assayed with the larger substrate, fetuin, the optimal pH for cp45 was about 4.9, whereas the optimal pH for the JS strain was about 6.3. Without being bound by theory, a lower pH optimum for 25 neuraminidase activity of cp45 as compared to that of wild-type HPIV-3 (JS) is consistent with the variant HN protein being an attenuating lesion of cp45 where *in-vivo* HPIV-3 infection initiates in regions of the respiratory tract which have a pH which is closer to the optimal pH of the wild-type JS strain than the optimal pH of cp45.

30 In an enzymatic kinetic study, the neuraminidase activities of cp45 and JS strains were determined using assays having neuraminlactose substrates with either 2→3 or 2→6 linkages. (Example 10). The kinetic studies were

conducted at a pH of 5.5, shown to be optimal for neuraminolactose. Comparison of the rate of change in activity for the cp45 and JS strains indicates that both strains have a similar preference for the 2 \rightarrow 3 linkage 5 (Fig. 11A), whereas cp45 has a greater preference than the JS strain for the 2 \rightarrow 6 linkage. (Fig. 11B). Moreover, cp45 has a greater preference for the 2 \rightarrow 3 linkage than for the 2 \rightarrow 6 linkage. (Compare Fig. 11A and Fig. 11B).

Without being bound by theory, the results of the 10 experiments involving neuraminidase activity assays cumulatively indicate that the variant HN protein of cp45 has an altered tertiary structure as compared to that of HPIV-3(JS) and that activity of the variant HN protein is likely temperature, pH, substrate and/or linkage 15 dependent. The decrease in neuraminidase activity restricts the release of the progeny virus particles from the infected cell surface. However, the decrease in activity by a factor ranging from about five to about 10 suggests that the variant HN protein is a relatively less 20 important contributing lesion as compared to the variant L protein. Moreover, nucleotide changes in the 3' leader region of cp45 relative to the that of the wild-type strain are also suspected of affecting the cold adaptive, 25 temperature, sensitivity and/or attenuation properties of cp45.

Although the transcriptional activity and neuraminidase activities of cp45 are reduced relative to those of wild-type HPIV-3, other biological properties were not significantly altered. Early studies indicated 30 that the antigenic sites of the envelope glycoproteins, defined by reactivity to a panel of monoclonal antibodies remained unaffected in cp45 as compared to the wild-type strain. (Example 3). However, some modulation of the surface antigens of cp45 was indicated in further studies 35 in which the antigenic relatedness of the neuraminidase active sites of cp45 and HPIV-3 (JS) was compared using

antibodies and antiserum known to inhibit the neuraminidase activity of wild-type HPIV-3. Inhibition of cp45 and HPIV-3 (JS) neuraminidase activity was tested with three monoclonal antibodies (2-14-1, 13-9-6-2 and 5 170/8) and with a monospecific rabbit antiserum to affinity purified HN. (Example 11). When fetuin was used as the substrate for determining inhibition of neuraminidase activity, no significant difference in antigenic sites between cp45 and HPIV-3 (JS) was observed 10 for any of the inhibiting antibodies or antisera. (Fig. 12A). When the relatively smaller neuraminlactose substrate was used however, the neuraminidase activity of the cp45 strain was less inhibited than the activity of the JS strain by the monoclonal antibodies 12-9-6-2 and 15 170/8. (Fig. 12B). The extent of inhibition of neuraminidase activity in the two strains was similar for the monoclonal antibody 2-14-1 and for the monospecific rabbit antisera. (Fig. 12B). Without being bound by theory, the variation in amino acid sequence of the 20 enzymatic site of the cp45 HN protein appears to have caused minor changes to the antigenic sites recognized by monoclonal antibodies 12-9-6-2 and 170/8, but has not had a detectable effect on other antigenic sites, including for example, the antigenic site recognized by the 2-14-1 25 antibody. Nonetheless, the variant HN protein retains the capability to elicit an immune response specific for HPIV-3, despite the minor change in conformational epitope. Similarly, transport of HN and F glycoproteins to the cell surface, and the hemagglutinin activity of 30 the HN protein, determined by an hemagglutinin activity assay, were not substantially different for the cp45 strain relative to the wild-type JS strain. (Example 3). Further, limited viral morphogenesis was observed at the nonpermissive temperature.

35 The attenuating lesions associated with mutations of the L gene and the HN gene of cp45 can be used to create

vaccines directed at other wild-type HPIV-3 viruses and, additionally, vaccines directed at target viruses other than HPIV-3. In general, target viruses can include any enveloped virus that has one or more surface antigen. As used herein, the term "surface antigen" refers to a protein or a portion thereof which is capable of generating an immune response *in vivo*, and generally includes surface proteins, surface glycoproteins and/or other moieties which are responsible for the attachment of the viruses onto host cells, which allow the viruses to penetrate into the host cells to establish infection, and/or which facilitate release of progeny virus from the infected host cells. Surface antigens of various viruses or virus strains are considered "different" from each other if they have different antigenic sites such that they generate different *in vivo* immune responses. For purposes herein, differences can be demonstrated using *in vitro* assays showing that the surface antigens are selectively screened or selectively inhibited by different antibodies. The target virus will generally be a wild-type strain, but could also include mutant viruses against which it is desirable to use a live, attenuated vaccine.

Preferred target viruses include related enveloped, negative-sense, single-stranded RNA viruses such as human parainfluenza virus type 1 (HPIV-1), human parainfluenza virus type 2 (HPIV-2), respiratory syncytial virus (RSV), human influenza virus type A, human influenza virus type B, mumps and measles viruses. Target viruses such as HPIV-1, HPIV-2, RSV, influenza and measles each have surface proteins which are involved with the viruses' attachment to and penetration into a host cell, and which can be considered functionally analogous to the F and HN proteins of HPIV-3. The nucleic acid sequences for encoding the surface proteins for each of these viruses are known. HPIV-1 and HPIV-2, like HPIV-3, each have two

surface glycoproteins, HN and F, which are functionally similar to HPIV-3's HN and F proteins. For both type 1 and type 2 parainfluenza viruses, the H portion of the HN protein and the F protein are related to attachment and 5 penetration, respectively, while the N portion of the HN protein is responsible for release of progeny virions. The nucleic acid sequences of the F gene and HN gene for HPIV-1 have been previously determined. (Merson et al. 1988; Matsuoka et al. 1990). The nucleic acid sequences 10 of the F gene and the HN gene for HPIV-2 have likewise been determined. (Hu et al. 1990; Precious et al. 1990; Kawano et al. 1990'; Kawano et al. 1990). RSV-A and RSV-B each have two surface glycoproteins, F and G. The G protein is functionally analogous to the hemagglutinin 15 activity of HPIV-3's HN protein; it has activities related to attachment onto a host cell. F is related to penetration of the nucleocapsid into the host cell. The nucleic acid sequences of the F gene and G gene for RSV-A have been determined. (Lopez et al. 1988; Martin- 20 Gallardo et al. 1991; Anderson et al. 1992; Martin-Gallardo et al. 1993; Collins et al. 1993). The nucleic acid sequences of the F gene and G gene for RSV-B have also been previously determined. (Baybutt and Pringle 1987; Sullender et al. 1990; Sullender et al. 1991). 25 These sequences or portions thereof have also been extensively compared. (Johnson and Collins 1988; Johnson and Collins 1988'). Influenza types A and B also have two surface glycoproteins: H and N. The H protein has activities related to attachment and penetration onto and 30 into a host cell. The N protein relates to release of progeny virions from the infected host. Although the antigenic sites for influenza viruses typically change every year or so, samples of current strains are readily available from the U.S. Center for Infectious Disease 35 Control, and the nucleic acid sequences defining the current surface glycoproteins can be determined

therefrom. Measles viruses also have two surface glycoproteins: HN and F. Like HPIV-3, the H portion of the HN protein and the F protein are related to attachment and penetration, respectively, while the N portion of the HN protein is responsible for release of progeny virions. Bovine RSV has two surface glycoproteins which are functionally analogous to the human RSV strains. The nucleic acid sequences for bovine RSV G and F glycoproteins have been determined. (Lerch et al. 1990; Walravens et al. 1990). While target viruses related to HPIV-3 by virtue of their molecularly and functionally similar surface proteins are preferred, the target viruses of the present invention can also include other enveloped viruses, such as other 15 paramyxoviruses, other orthomyxoviruses, retroviruses (e.g. human immunodeficiency viruses, HIV, which have, for example, surface proteins with attachment functions (HIV-GP120) and penetration functions (HIV-GP41)), arenaviruses, coronaviruses, bunyaviruses, rhabdoviruses, 20 togaviruses, herpesviruses, poxviruses and hepadnaviruses. Preferable target viruses include enveloped viruses which reproduce in the cytoplasm. The target virus of the present invention may be specific to humans, specific to animals or common to both animals and 25 humans. Bovine RSV and cattle HPIV-3 (shipping fever virus) are typical animal viruses included within the scope of the present invention.

Vaccines directed at HPIV-3 viruses can be created by using genetic engineering techniques to create a 30 hybrid virus which is preferably an enveloped, negative-sense, single-stranded RNA virus. Such a hybrid virus can be created, in general, by replacing the wild-type L and/or HN genes in the genome of the target virus with L and/or HN genes which are mutated relative to the target 35 virus and which encode variant L and/or HN proteins having reduced polymerase and/or neuraminidase activity,

respectively. The hybrid virus is then combined with a pharmaceutically acceptable carrier to form an attenuated vaccine.

A hybrid virus suitable for use in a vaccine against an HPIV-3 target virus has a chimeric viral genome which comprises a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of the HPIV-3 target virus or which encodes one or more of the following proteins: the nucleocapsid protein [NP], the phosphoprotein [p(+C)], the matrix protein [M], and/or the fusion protein [F] of the wild-type HPIV-3 target virus. The viral genome further comprises HN and L genes. The HN gene of the viral genome can encode either the wild-type HN protein of the target virus or a variant HN protein having a neuraminidase activity which is less than the neuraminidase activity associated with the HN protein of the target virus at a temperature of about 39°C. Similarly, the L gene of the viral genome can encode either the wild-type L protein of the target virus or a variant L protein having an RNA-polymerase activity which is less than the RNA-polymerase activity associated with the L protein of the target virus at a temperature of about 39°C. In any case, either the HN gene or the L gene of the hybrid virus encodes a variant protein, such that the hybrid virus has at least one attenuating lesion (based on either the variant HN or the variant L proteins) relative to the wild-type HPIV-3 virus.

In one embodiment, the genome of the hybrid virus includes a nucleic acid sequence which encodes a variant L protein and a nucleic acid sequence which encodes a variant HN protein. Such a hybrid virus would, like cp45, have at least two attenuating lesions. Moreover, the 3' leader region of the hybrid virus can be a variant 3' leader region which has at least one nucleic acid variation relative to the 3' leader region of the wild-type HPIV-3 target virus. The cp45 3' leader region is a

preferred variant 3' leader region. Similarly, the genome of the hybrid virus can include a nucleic acid sequence which encodes variant NP, P(+C), M or F proteins having at least one amino acid variation relative to 5 their respective wild-type proteins. The cp45 NP, P(+C), M and F proteins are preferred variant proteins.

An alternative, slightly less attenuated hybrid virus has a genome which includes a nucleic acid sequence which encodes a variant L protein and a nucleic acid 10 sequence which encodes a wild-type HN protein. The 3' leader region of this hybrid virus can be a wild-type or variant 3' leader region and the viral genome can also include nucleic acid sequences which encode either wild-type or variant NP, P(+C) M and F proteins. An exemplary 15 hybrid virus is a modified cp45 virus where the HN gene of cp45 has been replaced with the HN gene of wild-type HPIV-3 (JS). Specifically, such a modified cp45 hybrid virus would have a viral genome which includes, in succession from its 3' end, (i) a nucleic acid sequence 20 which is the same as the nucleic acid sequence of the 3' leader region of cp45, (ii) a nucleic acid sequence which encodes the nucleocapsid protein [NP] of cp45, (iii) a nucleic acid sequence which encodes the phosphoprotein [P(+C)] of cp45, (iv) a nucleic acid sequence which 25 encodes the matrix protein [M] of cp45, (v) a nucleic acid sequence which encodes the fusion protein [F] of cp45 or of the target virus, (vi) a nucleic acid sequence which encodes the hemagglutinin-neuraminidase protein [HN] of the target virus, and (vii) a nucleic acid 30 sequence which encodes the L protein of cp45. A vaccine comprising a hybrid virus having a wild-type HN protein and a variant L protein would be slightly less attenuated than a vaccine comprising a virus which included both variant HN and variant L proteins. For example, a 35 vaccine which includes the modified cp45 virus described above (having a wild-type (JS) HN protein and a cp45 L

protein), is less attenuated than cp45 relative to the wild-type JS strain. These vaccines may be of commercial significance, for example, if clinical trials with cp45 show that a slightly higher level of 5 replication and resulting higher immune response would be desirable.

Vaccines directed at viruses other than HPIV-3 can also be created. For example, the region of the genome of the target virus that encodes one or more surface 10 glycoproteins or surface antigens of the target virus (typically proteins responsible for attachment, penetration and release of the virus and virus progeny) may be combined, through genetic engineering techniques, with the region of the cp45 viral genome which encodes 15 proteins responsible for replication and internal structure. The resulting hybrid virus will have the temperature sensitive attenuation properties contributed by the cp45 genome and the virus-specific antigenic properties of the target virus. As such, the hybrid 20 virus will have a predictable level of safety and immunogenicity and be suitable for use as a vaccine in humans.

A vaccine developed from cp45 in combination with a non-HPIV-3 target virus comprises an enveloped, negative-sense, single-stranded RNA hybrid virus and an appropriate pharmaceutical carrier. The hybrid virus includes a nucleic acid sequence which encodes at least one surface antigen of a target virus. The encoded 25 surface antigens are antigenically different from the surface antigens of HPIV-3 viruses such as cp45. The hybrid viral genome also includes a nucleic acid sequence 30 which encodes either or both of the following: (i) a variant large protein [L] having an RNA-polymerase activity which is less than the polymerase activity 35 associated with the target virus at a temperature of about 39°C and/or (ii) a portion of the cp45 HN protein

having neuraminidase activity which is less than the neuraminidase activity of the target virus at a temperature of about 39°C. The encoded portion of the HN protein is preferably at least about 50 amino acid 5 residues in length, more preferably at least about 100 amino acids residues in length, even more preferably at least about 200 amino acid residues in length and most preferably at least about 220 amino acid residues in length. The encoded portion preferably includes amino 10 acid residue 384 of the HN protein of cp45, or a functionally similar variant residue within about 5 amino acid residues of residue 384 of cp45. The encoded portion most preferably includes an amino acid sequence which is the same as the amino acid sequence from residue 15 160 to residue 385 of cp45.

The possibility for reversion to a non-attenuated strain is lower if the genome of the hybrid virus more closely resembles the cp45 genome in the 3' leader region and in the regions encoding the NP, P[+C] and M proteins. 20 Hence, a preferred hybrid virus suitable for use in vaccines against target viruses other than HPIV-3 strains has a chimeric genome which comprises, in succession from its 3' end: a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of a 25 cp45 viral genome; nucleic acid sequences which encode the nucleocapsid protein, [NP], the phosphoprotein, P[+C], and the matrix protein, [M], of cp45; a nucleic acid sequence which encodes at least one surface antigen of an enveloped target virus other than an HPIV-3 virus, 30 and a nucleic acid sequence which encodes a variant L protein.

As referred to in the aforementioned hybrid viruses directed against HPIV-3 and non-HPIV-3 target viruses, a variant L protein is a HPIV-3 L protein which has at 35 least one variation in amino acid sequence compared to its structurally most closely associated wild-type HPIV-3

L protein (that is, relative to the wild-type protein from which the variant protein was derived or relative to the wild-type protein encoded by the gene from which a mutated gene encoding the variant protein was derived).

5 For purposes herein, a HPIV-3 L protein is a protein having an amino acid sequence which has at least about a 90% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein. The sequence identity between the variant L protein and the wild-type HPIV-3

10 (JS) L protein is, in order of increasing preference, more preferably at least about 95%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, at least about 99.7% and at least about 99.8%. Since the JS strain L protein has 2,258 amino acids and

15 since, in general, most HPIV-3 L proteins are comprised of over 2000 amino acid residues, a 99.8% sequence identity corresponds to about 4 variations in amino acid sequence between the wild-type and variant proteins. Likewise, the variant HPIV-3 L protein cannot be the same

20 protein as the wild-type polymerase protein of the target virus (regardless of whether the target virus is an HPIV-3 virus or a non-HPIV-3 virus). Hence, the variant L protein has at least one variation in amino acid sequence relative to the L protein (or the functionally analogous

25 polymerase protein) of the target virus. Moreover, the variant L protein has RNA-polymerase activity which is less than the polymerase activity normally associated with the target virus at a non-permissive temperature ranging from about 37 °C to about 40 °C and preferably at

30 a temperature of about 39°C. The polymerase activity of the variant L protein is preferably at least about 10% less than the polymerase activity of the target virus. The polymerase activity of the variant L protein is more preferably, in order of increasing preference, at least a

35 factor of 10², 10³, 10⁴, 10⁵ and 10⁶ less than the polymerase activity of the target virus.

The variant L protein is most preferably a mutant HPIV-3 (JS) L protein. That is, a preferred variant L protein has at least one variation in amino acid sequence relative to the L protein of HPIV-3 (JS). While the term 5 variation is intended to include additions, deletions or substitutions in amino acid residues, the variation is preferably a substitution which is functionally analogous to the substitutions of the cp45 L protein relative to the wild-type HPIV-3 (JS) L protein. Hence, the 10 variation in amino acid sequence relative to HPIV-3 (JS) is preferably within about (ie, plus or minus) five amino acid residues of residues 942, 992 or 1558. More specifically, the variation in amino acid sequence relative to HPIV-3 (JS) preferably includes one or more 15 of the following substitutions: His for Tyr at residue 942, Phe for Leu at residue 992 and Ile for Thr at residue 1558. The variant L protein more preferably has at least two variations in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein: His for Tyr at 20 residue 942 and Phe for Leu at residue 992. The variant L protein has, even more preferably, all three of the variations in amino acid sequence of the cp45 L protein, and may include other variations as well. While other substitutions or other variations may, in addition to 25 those described immediately preceding, also exist in the amino acid sequence of the variant L protein, a variant HPIV-3 (JS) L protein having only these recited substitutions and conferring reduced polymerase activity are generally sufficient. The variant L protein is most 30 preferably the L protein of cp45.

A variant hemagglutinin-neuraminidase (HN) protein is, as referred to in the aforementioned hybrid viruses, a HN protein having at least one variation in amino acid sequence relative to its structurally most closely 35 related wild-type HPIV-3 HN protein. The variant HN protein has an amino acid sequence which has at least

about a 90% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) HN protein. The sequence identity between the variant HN protein and the wild-type HPIV-3 (JS) HN protein is, in order of 5 increasing preference, more preferably at least about 95%, at least about 97%, at least about 98%, at least about 99% and at least about 99.5%. Since HPIV-3 HN proteins typically comprise at least about 400 amino acid residues, a 99.5% sequence identity corresponds to about 10 2 variations in amino acid sequence between the wild-type and variant proteins. Likewise, the variant HPIV-3 HN protein cannot be the same protein as the wild-type neuraminidase protein of the target virus; the variant HN protein has at least one variation in amino acid sequence 15 relative to the neuraminidase protein (or the functionally analogous release protein) of the target virus. Moreover, the variant HN protein has neuraminidase activity which is less than the neuraminidase activity normally associated with the 20 target virus at a non-permissive temperature ranging from about 37 °C to about 40 °C and preferably at a temperature of about 39°C. The neuraminidase activity of the variant HN protein is preferably less than the polymerase activity of the target virus by a factor of at 25 least about 3, more preferably by a factor of at least about 5, even more preferably by a factor of at least about 10 and most preferably by a factor of at least about 15.

The variant HN protein is preferably a mutant HPIV-3 30 (JS) HN protein which has at least one variation in amino acid sequence relative to the HN protein of HPIV-3 (JS). While the variation can be an addition, deletion or substitution, the variation is preferably a substitution 35 which is functionally analogous to the substitutions of the cp45 HN protein relative to the wild-type HPIV-3 HN protein. Hence, the substitution is preferably at or

within (ie, plus or minus) about five amino acid residues of amino acid residue 384 of the JS strain HN protein. The variant HN protein more preferably includes the substitution of Ala for Val at position 384 or another 5 functionally equivalent substitution within 5 residues thereof. Other variations may, in addition to those described immediately preceding, also exist in the amino acid sequence of the variant HN protein; however, a variant HPIV-3 (JS) HN protein having only the single 10 amino acid substitution recited and conferring reduced neuraminidase activity is generally sufficient. The variant HN protein is most preferably the HN protein of cp45.

The genes described above as being included in the 15 genome of a hybrid virus are, in practice, operatively linked for expression. The exact sequence in which the genes are linked is not narrowly critical. Moreover, the various viral genomes may further include non-coding nucleic acid residues between the various genes.

20 In addition to an attenuated hybrid virus, the vaccine of the present invention also comprises a pharmaceutically appropriate or acceptable carrier for the attenuated hybrid virus. Typical carriers include the tissue culture fluid in which the virus is grown, 25 diluents such as phosphate-buffered saline and/or stabilizers such as gelatin.

The method for producing an attenuated hybrid virus 30 suitable for use as a human vaccine against a target wild-type virus includes genetic engineering techniques applied to insert target gene sequences encoding target 35 surface glycoproteins into the cp45 genome in place of the corresponding surface glycoprotein genes in the cp45 genome or replacement of naturally-occurring genes encoding neuraminidase proteins or polymerase proteins in target viruses with variant proteins having reduced activities. The method detailed below is an exemplary

method. Those skilled in the art will appreciate that variations in this method and other methods are also suitable to produce a hybrid virus. The standard methods in molecular biology useful for these purposes can be 5 found in a variety of well-known references, including for example Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory Press, 2nd Ed. 1989. The methods can be used, in particular, to produce attenuated hybrid viruses for use in vaccines against HPIV-1, HPIV-10 2, RSV, influenza and measles target viruses.

To produce a cp45 hybrid virus in which cp45 is used as a backbone and combined with surface antigens from a target virus, the viral genome of cp45 is first converted into full-length cDNA clone. Typically, several 15 different portions of the genome are amplified using PCR and ligated in successive steps into a full length cDNA clone. The regions of the target virus genome encoding the target's surface glycoproteins are also converted into a cDNA clone. Genomic regions of target viruses 20 having negative-sense or positive-sense, single-stranded RNA genomes, such as HPIV-1, HPIV-2, RSV, measles and influenza viruses, are converted in the same manner as cp45. DNA from viruses having DNA genomes can be directly ligated into the DNA plasmid vector.

25 The cDNA clone of the cp45 genome is then incorporated into a plasmid vector. Plasmid vectors such as pBluescriptII (Stratagene) or other commercially available vectors which are suitable for subsequent transfection and expression in a mammalian host cell may 30 be used. Briefly, the cDNA clone and plasmid vector are combined using restriction enzyme digestion and ligation reactions. The recombinant plasmid is then cloned and purified.

35 Genetic manipulations are conducted to replace the regions of the cp45 cDNA genome which encode the F and HN proteins with the cDNA or DNA copy of the target virus'

genes which encode the target's one or more surface glycoproteins.

Negative-sense, single-stranded RNA hybrid viruses are then produced from the recombinant viral genome by 5 transfecting the hybrid cDNA plasmid vector into cells such as mammalian cells for synthesis of progeny viral genomes, viral proteins and viral particles using reverse genetic techniques. (Palese 1995; Lawson et al. 1995; Schnell et al. 1994). Briefly, the plasmid vector 10 containing the cDNA copies are transfected into a host cell which has been previously infected with a recombinant vaccinia virus expressing bacteriophage T7 RNA polymerase. Plasmid vectors that express HPIV-3 NP, P and L proteins, produced according to the method 15 described in Example 4, are cotransfected into the host cell. The cDNA is transcribed to produce full-length, negative-sense (genomic) RNA. Expression of the NP, L and P proteins facilitates synthesis of progeny hybrid virus. The hybrid virions are then isolated, grown in 20 appropriate mammalian cells and tested to verify temperature sensitive phenotype and associated attenuation.

Another practical application of the invention relating to the observation that attenuating lesions of 25 cp45 correlate to defects in the L and HN genes of cp45 is a method for determining whether a HPIV-3 virus or a cp45-hybrid virus is attenuated. As used herein, the term "cp45-hybrid" virus refers to a chimeric virus having genes which encode a variant L protein and/or a 30 variant HN protein, as such variant proteins are described above. Such a determination is made by confirming the presence of at least one variation in the region of the HPIV-3 genome which encodes the L protein relative to the corresponding region of the genome of 35 wild-type HPIV-3. Alternatively, defects in the region encoding the HN protein, and particularly at or within

about 5 residues of residue 384 can be indicative of decreased neuraminidase activity. A determination can, in the same manner, also be made as to whether a cp45-hybrid virus is attenuated. Verification of attenuation 5 is necessary in a variety of situations. For example, verification is useful in research laboratories, as quality control checks in commercial production of vaccines, as verification by regulatory agencies, and as final checks on new vaccine lots before administration to 10 a patient. Verification of attenuation is likewise useful to check the stability of a vaccine after it has been administered to a patient. Isolates from the patient may be checked to verify that the progeny virus have retained the temperature sensitive attenuated 15 phenotype.

A variety of methods for confirming the presence of nucleotide variations are known in the art. For example, the nucleic acid region which encodes the L protein could be sequenced in its entirety and compared to the wild-type gene for L. Alternatively, where the viral strain being tested is cp45 or a cp45 hybrid virus, the L gene could be cut with restriction enzymes near the expected variations at residues 942, 992 and 1558, and the smaller fragments could be sequenced for comparison with the L 20 gene of wild-type HPIV-3 or of cp45. A more preferred method would include isolating nucleic acid from the viral strain being tested in single-stranded form, hybridizing the viral nucleic acid to probes which flank the variations, amplifying the region between the probes 25 using PCR and sequencing the amplified regions of the L gene for comparison to wild-type HPIV-3 or to cp45. Other alternatives for determining point variations in gene sequences, such as single nucleotide extension reactions (Kuppuswamy et al. 1991) are also known in the 30 art. 35

The complementation assay of the present invention, described in detail in Examples 3 and 4, may also be used to confirm the presence of at least one variation in the L gene. This method not only verifies gene sequence 5 variation, but also simultaneously verifies the functional effect of such variations in the L gene. The dual nature of such a test is advantageous over sequencing information alone, due to the possibility of suppressor mutations. Briefly, a viral strain sample is 10 obtained from a new vaccine lot or as a purified patient isolate. If necessary, the sample is amplified by growing in a cell culture medium. A standard, first plaque assay is performed, as a control, by incubating at a non-permissive temperature (about 40°C), and measuring 15 replication. A complementation assay is then performed in which host cells are transfected with a plasmid vector that expresses wild-type HPIV-3 L protein and are also infected with the viral sample. (See Examples 3 and 4). Plasmid vectors which express wild-type NP and/or P 20 proteins may be cotransfected into the host cells. A second plaque assay is performed on the complemented viral sample, and the results are compared to the results of the first plaque assay. A variation in the sample virus's L gene will be indicated by a significant 25 increase, preferably at least a 10 fold increase, and most preferably a 100 fold increase, in replication of the complemented viral sample as compared to the non-complemented sample, as measured by plaque assays. In a similar manner, neuraminidase growth experiments and 30 activity assays can be conducted in the absence of and presence of exogenous neuraminidase to verify the presence of a defect in the HN gene.

The following non-limiting examples illustrate the principles and advantages of the invention.

EXAMPLES

As used in the following examples, cp45 was derived from wild-type HPIV-3 (JS strain), an isolate originally cultured from a child with febrile respiratory disease.

5 A cold-adapted mutant was selected after serial passage of the virus 45 times at 20°C and isolated by plaque purification (Belshe and Hissom 1982). The cp45 virus was subsequently grown at 32°C in continuous cell lines. In each of the experiments discussed below in which

10 comparative assays were used, the amount of initial virus present in the assay was determined using hemagglutinin assay analysis. Briefly, L-132 cells infected with cp45 virus and grown at 32°C for 72 h were removed from cell culture dishes using a cell scraper. Pelleted cells were

15 washed with PBS, sonicated and used for analysis of hemagglutination. Serial two fold dilutions of the sonicated virus-infected cell homogenate were made in 100 ul PBS (without Ca²⁺ and Mg²⁺) in a 96 well V bottom microtiter plate. Then 100 ul of a 0.5 % suspension of

20 guinea pig erythrocytes in PBS (without Ca²⁺ and Mg²⁺) was added to each well, and the plate was incubated at 4 °C for ~2 h until a clear button or HA was observed with the negative and positive controls, respectively.

25 Example 1: Temperature-Dependent Replication, Protein Synthesis and mRNA Synthesis of cp45

Unlike the wild-type HPIV-3 strain, the cp45 strain loses its replication ability at non-permissive higher temperatures (above about 37°C). This loss of replication activity contributes to the observed

30 attenuation in the cp45 vaccine. Moreover, a related decrease in virus-specific mRNA synthesis and in protein synthesis exists in the cp45 strain relative to the wild-type strain.

35 cp45 virus was absorbed into a cellular culture medium at 32°C for 1 hour and grown at 39.5°C for 24

hours. Infected cells were then shifted to 32°C for growth for an additional 24 hours. The virus titer in the culture supernatant was determined by plaque assay in L-132 cells. Infected cell monolayers were either stained with hematoxylin-eosin Y or overlaid with 0.9% agar and 0.005% neutral red for visualization of viral plaques. The results from at least three independent experiments showed consistent virus recovery (less than fivefold variation).

Comparison of cp45 and wild-type (JS) virus replication in L-132 cells at permissive (32°C) and nonpermissive (39.5°C) temperatures in a temperature-shift assay is shown in Table 1. Normal growth of both viruses was observed at the permissive temperature. However, poor replication (reduction of ~10⁶-fold) of cp45 was observed when the virus was absorbed on L-132 cells at 39.5°C and incubated at the same temperature. However, the virus showed some replication upon changing the incubation temperature from 39.5 to 32°C after 24 h. On the other hand, the wild-type virus exhibited similar replication at 39.5 and 32°C. cp45 virus replicated upon temperature shift from 39.5 to 32°C, thereby demonstrating the characteristic temperature-sensitive phenotype and indicating an absence of revertant virus at 39.5 or 32°C.

The virus-specific RNA synthesis occurring in the cp45 strain is likewise significantly lower than such synthesis in the wild-type strain. Hence, only low levels of messenger RNA (mRNA) are produced at the non-permissive temperature. In order to determine the overall viral transcriptional activity at the nonpermissive temperature, mRNA synthesis from the P protein gene of cp45 virus was studied by reverse transcription-PCR for comparison with that of the wild-type virus.

Briefly, L-132 cells were infected with cp45 or wild-type virus at a similar multiplicity of infection.

After virus adsorption at 32°C, cells were grown at 39.5°C for 24 h. Infected cells were treated with actinomycin D (10 µg/ml) for 14 h, and RNA was prepared by acid guanidinium thiocyanate-phenol-chloroform extraction. Amplification of the P mRNA was conducted by reverse transcription-PCR from the same quantities of total RNA (10 µg) and virus-specific sense (CCAAACAACAACTCCCAGATC, nucleotide positions 2740 to 2759) and anti-sense (TGCCTCCATAAGTGGGTCAA, nucleotide positions 3280 to 3299) synthetic oligonucleotide primers. The amplification reaction was performed by using an automatic thermocycler (Perkin-Elmer Cetus), with cycling parameters of denaturation at 94°C for 1 min, primer annealing at 50°C for 1.5 min, and primer extension at 72°C for 2 min. As an internal standard, amplification of the actin mRNA was similarly carried out by reverse transcription-PCR by using the same RNA preparations and β-actin gene-specific sense (GCATGGAGTCCTGTGGCATCCACG, nucleotide positions 2563 to 2586) and anti-sense (CTAGAACATTTGCGGTGGACGAT, nucleotide positions 2977 to 3000) primers. A plasmid DNA containing the P protein gene of HPIV-3, kindly provided by Mark S. Galinski (The Cleveland Clinic Foundation, Cleveland, Ohio), was also used as a positive control in the PCR amplification. A PCR-amplified ~559 bp fragment from the P protein gene plasmid DNA was isolated by electrophoresis in a 0.8% agarose gel. The DNA band was excised, eluted by using an ultrafree MC column (Millipore Corporation, Bedford, Mass.), and radiolabeled with [α -³² P]dCTP by the random primed oligonucleotide labeling method by using a commercially available kit (Boehringer Mannheim Biochemicals, Indianapolis, Ind.), for use as a probe. An actin probe was similarly prepared for use in Southern hybridization.

mRNA synthesis was tested by comparing the levels of message between the two RNA preparations in a parallel

experiment. The reaction products from different cycles of PCR amplification were analyzed by agarose gel electrophoresis followed by ethidium bromide staining and showed a significant difference in the levels of message 5 generated from cp45 and wild-type virus. On the other hand, similar message levels of the actin gene, studied as an internal control, were observed for the RNA isolated from cp45 and wild-type virus-infected cells. A similar observation was noted following Southern 10 hybridization of the electrophoresed DNA. The typical amplification profile of the PCR products from viral mRNA is shown in Fig. 2A. A semiquantitative approach was taken for the estimation of the differences between these messages by slot blot hybridization with fourfold 15 dilutions of a single cDNA sample. A representative example of the results, shown in Fig. 2B, further indicates differences in the message of the P gene from cp45 and wild-type virus-infected cells at 15 and 20 cycles of PCR amplification. Message from the P protein 20 gene of cp45 virus was estimated to be approximately 17% of that of wild-type virus by PhosphorImaging analysis.

Protein synthesis at the higher non-permissive temperature was also significantly lower in the cp45 strain as compared to the wild-type strain. cp45 virus 25 polypeptide synthesis was analyzed by a pulse-chase experiment followed by immunoprecipitation with a hyperimmune rabbit antiserum to HPIV-3 or monoclonal antibodies to HN and NP.

Briefly, virus-infected cells were grown at 39.5 or 30 32°C for 24 h and pulsed with ³⁵S-protein label (Amersham Corporation, Arlington Heights, Ill.) for 1 h. Labeled cell lysates were immunoprecipitated after a chase of 0, 1, 2, 3, and 4 h with hyperimmune rabbit antiserum to HPIV-3 or with a pool of anti-HN and anti-NP monoclonal 35 antibodies. Immunoprecipitates were analyzed by sodium

dodecyl sulfate-polyacrylamide gel electrophoresis, followed by autoradiography.

The results show a major difference in the synthesis of viral proteins between the wild-type and cp45 virus.

5 Synthesis of wild-type virus polypeptides during the pulse period was not processed or modified further during the 4-h chase period (Fig. 3). On the other hand, cp45 virus polypeptide synthesis appeared to be extremely weak or almost undetectable. However, synthesis of cp45 and
10 wild-type virus polypeptides was found to be similar when cells were grown at 32°C.

Example 2: Temperature-Dependent Neuraminidase Activity of cp45

cp45 virus was grown on L-132 cells at 32 or 39.5°C, 15 and the virus-infected cell homogenate was analyzed for neuraminidase activity. The cp45 strain exhibited a reduced neuraminidase activity at the nonpermissive, higher temperature. Such a decrease in activity inhibits the release of progeny virus particles from an infected 20 cell surface.

Briefly, 100 µl of 0.2 M sodium acetate buffer (pH 5.5) was mixed with an equal volume of infected cell homogenate with a known number of hemagglutinin activity units. Then, 0.1 ml of bovine fetuin (15 mg/ml, type IV; 25 Sigma Chemical Company, St. Louis, Mo.) dissolved in the same buffer was added to the reaction mixture, and the mixture was incubated at 37°C overnight. The amount of released neuraminic acid in the reaction mixture was determined. Wild-type parent virus was also included in 30 this study for comparison.

When tested with two different molecular-size substrates, the neuraminidase property of the cp45 virus incubated at the nonpermissive temperature showed lower activity, by a factor ranging from about 4 to about 10, 35 than cells infected with the wild-type virus (Table 3).

Example 3: Evaluation of Other Biological Properties of cp45

Antigenic relatedness of cp45 and the wild-type parent virus strain was initially compared by 5 hemagglutination (HA) inhibition and neutralization assays using a monospecific rabbit antiserum to affinity-purified HPIV-3 HN glycoprotein. Rabbit anti-HN showed similar HA inhibition activities and neutralization titers (within twofold variation) with both the virus 10 strains.

Subsequently, representative anti-HN and anti-F monoclonal antibodies recognizing distinct antigenic sites of the HN and F glycoprotein molecules were tested by enzyme-linked immunosorbent assay (ELISA). Dynatech 15 polyvinyl plates (Immulon I) were coated with 1 μ g of freeze-thaw disrupted virions per well. Monoclonal antibodies were tested at twofold serial dilutions for each virus strain (cp45 and the wild type), and the results were compared with the linear slopes of the 20 reactivity pattern.

The results are presented (Fig. 4) as the mean optical densities from three independent experiments, showing variations within 0.05 to 0.08. The antibodies recognized the HN and F glycoproteins of cp45 virus and 25 by ELISA showed titers similar to that of the wild-type virus. This suggests that the antigenic sites of cp45 virus were not altered as a result of its adaptation for growth at 20°C.

Moreover, the cp45 virus glycoproteins are processed 30 and transported to the cell surface even at the nonpermissive temperature. Infected L-132 cells were tested 24 h after infection by immunofluorescence with specific monoclonal antibodies to HN and F. Confluent monolayers of L-132 cells were grown on coverslips, 35 infected with the virus, and incubated at 32 or 39.5°C. At 24 h postinfection, cells were washed with phosphate-

buffered saline and tested with monoclonal antibodies. At both incubation temperatures (32 and 39.5°C), cp45-infected cells showed immunofluorescence on the cell surface.

5 HA and fusion activity was also investigated. cp45 virus grown at 32°C was pelleted by ultracentrifugation and used for an HA assay to test the functional property of the HN glycoprotein. As the cp45 virus showed extremely poor growth at 39.5°C, we tested the HA 10 activity of infected cell homogenates following incubation at the nonpermissive temperature. Results showed detectable HA activity of the cp45 virus grown at the permissive or nonpermissive temperature. cp45 virus-infected LLC-MK₂, Vero, and L-132 cells also showed 15 formation of multinucleated giant cells or syncytium formation, a characteristic of virus fusion activity, when grown at 32°C. However, fusion activity was significantly reduced upon incubation of cp45 virus-infected cells at 39.5°C, probably because of poor 20 replication of the virus at the nonpermissive temperature.

Example 4: Expression of HPIV-3 NP, P and L Wild-Type Proteins

Wild-type NP, P and L proteins of HPIV-3 (JS) strain 25 were expressed for use in co-expression assays. The molecular cloning and sequence analysis of the HPIV-3 NP, P, and L genes have been previously described. (Galinski et al. 1988; Galinski et al. 1986; Galinski et al. 1986'). Briefly, all genes were removed from their 30 recombinant vectors by restriction endonuclease digestion and ligated into the appropriate sites of pcDL-SR beta 8.2 vector DNA. This vector is derived from pcDL-SR alpha-296 and contains a polyvalent restriction site with flanking T7 and SP6 promoter sequences downstream from 35 the SR alpha promoter. pcDL-SR beta 8.2 is a

multifunctional vector, and gene expression can be driven by using a simian virus 40 (SV40) early promoter or alternatively by using a vaccinia virus expressing T7 RNA polymerase.

5 Plasmids containing nucleic acid regions which encode the NP, P and L proteins were incorporated into DNA vectors. Plasmid pSP18-NP, which contains the NP gene, was first digested with *Sph*I, and the resulting cohesive end was repaired with T7 DNA polymerase. The 10 gene was then released from the vector with *BAM*HI and ligated into pcDL-SR beta 8.2 which had been digested with *Eco*RI, subsequently repaired with Klenow fragment, and then further treated with *BAM*HI. Plasmid pSP19-P, which contains the P gene, was digested with *BAM*HI and 15 *Pvu*II to release the P gene. The gene was subsequently ligated into pcDL-SR beta 8.2 which had been digested with *Xba*I, subsequently repaired with Klenow fragment, and then further treated with *BAM*HI. Plasmid pGEM3-L, containing the L gene, was first digested with *Hind*III, 20 and the resulting cohesive end was repaired with Klenow fragment. The L gene was then released from the vector with *Sac*I and cloned into pcDL-SR beta 8.2 which has been digested with *Eco*RI, subsequently repaired with Klenow fragment, and then further treated with *Sac*I.

25 All ligation reactions consisted of vector and gene fragments with compatible ends which would force ligation of the inserts in the desired orientation relative to the SR alpha and T7 promoters. Recombinant clones were randomly picked and further analyzed by restriction 30 endonuclease digestion to confirm the orientation and efficacy of the subcloning. The gene termini were confirmed by dideoxy sequence analysis (U.S. Biochemical, Cleveland, Ohio) to ensure that the initiating methionine and termination codons were maintained.

35 To examine the biological properties of the various nucleocapsid-associated proteins, we initially tested for

the protein expression of L (L-11), P (P-1), and NP (NP-1) in a transient expression system, using a recombinant vaccinia virus containing the bacteriophage T7 RNA polymerase gene (vTF7-3). HeLa-T4 cells, which are 5 relatively resistant to the cytopathic effect of vaccinia virus, were infected with vTF7-3 and transfected with plasmids containing the HPIV-3 L, P, or NP gene, using Lipofectamine (Bethesda Research Laboratories, Gaithersburg, Md.).

10 Expression of the viral L, P and NP proteins was detected after 20h in [³⁵S]methionine- [³⁵S]cysteine-labeled transfected cell lysates by immunoprecipitation with a hyperimmune rabbit antiserum to HPIV-3 or a monoclonal antibody to NP (Fig. 5A). Immunoprecipitates were 15 analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and autoradiography. To obtain better resolution of the large-molecular-size L protein, immunoprecipitates were also separated in a lower-percentage polyacrylamide gel (Fig. 5B).

20 Immunoprecipitated L, P, and NP polypeptides from the corresponding DNA-transfected cells were indistinguishable in size from the authentic viral proteins. The amount of the L protein appeared to be lower than that of the P or NP protein immunoprecipitated 25 by the antiserum from transfected cell lysates.

Example 5: Complementation of cp45 with Wild-Type Proteins

This example considers whether CV-1 cells which were transiently expressing the L, P or NP proteins could 30 rescue (that is, increase the replication of the virus, as measured by plaque assay) cp45 at the nonpermissive temperature. Briefly, CV-1 cells were cotransfected with the plasmid vector pRSV-T (encoding the SV40 large T antigen driven by a Rous sarcoma virus long terminal 35 repeat) and one or more recombinant plasmids containing

the NP, P, or L gene and incubated at 37°C. Twenty hours posttransfection, the expressing cells were infected with cp45 or wild-type virus at a multiplicity of infection of 1, and infected cells were incubated for an additional 28 h at 39.5°C. Following incubation, cell culture medium was harvested and HPIV-3 titers were determined by plaque assay in L-132 cells at permissive (32°C) and nonpermissive (39.5°C) temperatures. Infected cell monolayers were stained with hematoxylin and eosin-Y or, alternatively, overlaid with 0.9% agar and 0.005% neutral red for visualization of viral plaques.

Although the vaccinia virus system provided excellent levels of expression, because of the concern regarding the use of a viral vector which causes extensive cytopathic effect in the cell monolayer and the difficulties inherent to measuring HPIV-3 replication in vaccinia virus coinfection experiments, we used an expression system which did not require the use of vaccinia virus to drive transcription of our plasmid vectors.

The vector pcDL-SR beta 8.2 contains a promoter, designated SR alpha, consisting of the SV40 early promoter and the R segment and part of the U5 sequence (R-U5') of the long terminal repeat of human T-cell leukemia virus type 1. The vector also contained the SV40 origin of replication and gives significant levels of protein expression in COS-1 or COS-7 cells, in which the plasmids are amplified by the endogenous levels of T antigen. The utility of this expression system was extended to CV-1 cells by coexpression in *trans* of the large T antigen from another plasmid vector, pRSV-T (35), kindly provided by James Pipas, University of Pittsburgh.

The transfected CV-1 cells were tested initially for intracellular expression of the viral proteins by immunofluorescence. Briefly, cells were fixed with acetone-methanol (1:1) for 10 min at -20°C. A

hyperimmune rabbit antiserum to HPIV-3 (thoroughly preadsorbed with mock-transfected cells) was used as the primary antibody, and a fluorescein isothiocyanate tagged mouse anti-rabbit immunoglobulin G was used as the second antibody. Cells were examined at a magnification of x600 on a Nikon microscope equipped for epifluorescence, and digital photographs were captured by using a computer imaging system (Oncor Image Systems, Inc.).

As shown in Fig. 6, L and P appeared to form small inclusions, whereas NP seemed to give a more homogeneous, punctate staining pattern. Negative control cells did not show any detectable immunofluorescence.

The results of a typical complementation experiment are shown in Table 2; similar results were achieved in assays performed in triplicate. Virus yield at 39.5°C showed significant levels of cp45 replication at the nonpermissive temperature. These results indicate that the wild-type L protein was biologically functional and could complement the temperature sensitive mutation of the cp45 L protein, whereas expression of P and NP in the absence of L was nonfunctional. The virus titer represents a complementation efficiency of approximately 950 and 11,500 PFU of virus per 3 x 10⁶ cells. Cells transfected with L, P, and NP show a 10-fold increase in cp45 virus yield compared with cells transfected with L alone or with L and P. This may be due to interactions among these proteins for the formation of the nucleocapsid complex for efficient virus replication. However, their specific interactions during virus replication remain to be determined. The results of this example further support the role of the L protein as an RNA-dependent RNA polymerase activity essential for transcription and the life cycle of HPIV-3. Other cell lines, not transfected with the L gene, failed to produce detectable virus titers.

Example 6: Ability of HPIV-1 L Protein to Complement cp45 and Retention of Temperature Sensitive Phenotype in cp45 Progeny

cp45 virus produced from L-gene-transfected CV-1
5 cells at the nonpermissive temperature should remain
temperature sensitive for growth despite their ability to
replicate in L-expressing cells. At least 10 plaque-
purified virus stocks of the rescued progeny virus were
examined, and all virus stocks were found to have
10 maintained their temperature sensitive property.

Further, L-protein complementation of cp45 is heterotypic exclusive. L-132 or primary rhesus monkey kidney cells, when coinfecte^d with HPIV-1 and cp45, did not rescue growth of cp45 at the nonpermissive temperature.

Example 7: Plaque Assays for cp45 and HPIV-3 (JS) With or Without Exogenous Neuraminidase

Growth characteristics of cp45 and wild-type (JS) virus strains were determined without and with exogenous neuraminidase. The cp45 and, in separate experiments, the JS virus were adsorbed on L-132 cells at 32°C for 1 h and grown in culture medium with or without the addition of bacterial neuraminidase isolated from *C. perfringens* for the indicated time frame. Virus titer in the culture supernatant was determined by plaque assay on L-132 cells as described previously. (Belshe and Hissom, 1982). Infected cell monolayers were stained with hematoxylin-eosin-Y or overlaid with 0.9% agar and 0.005% neutral red for the visualization of viral plaques. Each assay was repeated three times.

The results are shown in Figure 7A for cp45 and in Figure 7B for the JS strain, with the error bars indicating standard deviations of the three independent assays. Figure 7A shows that cp45 virus titers taken after about 50 hours of incubation in a culture medium lacking exogenous neuraminidase were about five to

fifteen times lower than a corresponding titer taken after incubation in a culture medium containing exogenous neuraminidase. Figure 7B shows, in contrast, that wild-type JS virus titers were virtually identical after about 5 25 hours regardless of whether or not exogenous neuraminidase was present in the culture medium.

Example 8: Localized Fusion Activity of cp45 and Inhibition Thereof with Exogenous Neuraminidase

L-132 cells were infected with cp45 at a low 10 multiplicity of infection and grown with or without exogenous neuraminidase to evaluate the cytopathic effect of the virus. Analogous experiments using the HPIV-3 (JS) strain were conducted for comparison. Cells were infected at a multiplicity of infection (moi) of 0.1. A 15 low multiplicity of virus infection was used so that only a small number of cells were infected early, thereby allowing for monitoring the nature of the cytopathic effect in the cell monolayer while the cells were incubated at 32 °C for 36 hours in a culture in which 20 exogenous neuraminidase was absent. In separate experiments, infected cells were incubated in culture medium which included 50 ug (0.5 U) bacterial neuraminidase/ml.

The results are shown in Figures 8A through 8D. 25 Figures 8A and 8B are photos of cells infected with cp45 and HPIV-3 (JS), respectively, after growth in culture without exogenous neuraminidase. cp45 infected cells exhibited significant localized fusion, as indicated by the presence of multinucleated giant cell or syncytia 30 formation (Fig. 8A). Such localized fusion was not observed for JS-strain infected cells (Fig. 8B). Figures 8C and 8D are photos of cells infected with cp45 and HPIV-3 (JS), respectively, after growth in the presence of exogenous neuraminidase. The degree of localized cell 35 fusion for cp45 infected cells was significantly reduced

(Fig. 8C) and indicated a cytopathic effect similar to that observed for JS-strain infected cells (Fig. 8D).

Example 9: Immunofluorescence Staining Showing Restricted Distribution of Neuraminidase in cp45 Infected Cells

5 The distribution of the variant HN protein in L-132 cells infected with cp45 at 33°C was investigated using surface immunofluorescence techniques. Briefly, L-132 cells grown on cover slips were infected with cp45 or JS virus at multiplicity of infection of 0.01. After 10 adsorption of the virus, cells were incubated with or without exogenous neuraminidase in the culture medium at 33 °C for 36 h. Infected cells were washed and reacted with a monoclonal antibody (13-9-6-2) to the HN glycoprotein of HPIV-3 for surface immunofluorescence.

15 The results are shown in Figures 9A through 9D. Figures 9A and 9B are photos of cells infected with cp45 and HPIV-3 (JS), respectively, after growth in culture without exogenous neuraminidase. The distribution of the variant HN protein was substantially localized (Fig. 9A) 20 compared to distribution of the wild-type JS HN protein (Fig. 9B). Figures 9C and 9D are photos of cells infected with cp45 and HPIV-3 (JS), respectively, after growth in the presence of exogenous neuraminidase. Under these conditions, the distribution of variant HN protein 25 cp45 infected cells (Fig. 9C) was similar to the distribution of wild-type HN protein in JS-strain infected cells (Fig. 9D).

Example 10: Neuraminidase Activity Assays: pH Optima and Kinetic Studies

30 L-132 cells infected with cp45 virus and grown at 32°C for 72 h were removed from cell culture dishes using a cell scraper. Pelleted cells were washed with PBS, sonicated and used for analysis of neuraminidase activity. Neuraminidase activity was determined by

mixing 50 ul of 0.5 M phosphate buffer of known pH with an equal volume of infected cell homogenate of known hemagglutination units. Different size substrates, Fetuin (type IV) (15 mg/ml), 3'-N-acetylneuramin-lactose (1 mg/ml) or 6'-N-acetyl-neuramin-lactose (1 mg/ml) (Sigma Chemical Company, St. Louis, MO) dissolved in water were added to the reaction mixture and incubated at 37°C overnight. pH was controlled during incubation at various values during separate experiments. Released neuraminic acid in the reaction mixture was determined using spectrophotometric techniques. HPIV-3 (JS) infected cells were processed in a similar manner to the cp45 infected cells and analogous activity analyses were conducted for comparison.

In one set of experiments, the pH optima of cp45 neuraminidase activity was analyzed and compared to that of the parent JS strain. Figure 10A shows the variation in neuraminidase activity of the cp45 virus with pH when tested using fetuin or neuraminlactose assays at the nonpermissive temperature (39.5 °C). For cp45, the optimal pH was about 5.5 when the neuraminlactose assay was used (Fig. 10A - closed circles), but was lower (about 4.9) when the fetuin assay was used (Fig. 10A - open circles). Figure 10B shows the variation in neuraminidase activity of the HPIV-3 (JS) virus with pH in analogous experiments. For the JS-strain, the optimal pH using the neuraminidase assay was, like cp45, about 5.5 (Fig. 10B - closed circles). However, when the fetuin assay was used to determine the optimal pH for the JS strain (Fig. 10B - open circles), the optimal pH was higher (about 6.3). Referring to either Figure 10A or 10B, a comparison of the absolute values of neuraminidase activity determined by the different assay substrates is not particularly instructive, as the absolute activity reported for each of the two substrates appears to have been influenced by the initial amount of virus present in

the respective assays. The bars on Figures 10A and 10B indicate standard deviations from three separate experimental runs.

In another set of experiments, enzyme kinetic studies were done at the initial stage of incubation with the two different linkages of the low molecular weight neuraminlactose substrates: 2 \rightarrow 3 and 2 \rightarrow 6 linkages. The pH was maintained at 5.5 -- the enzymatic optimum for the neuraminlactose substrate for both cp45 and wild-type JS strains. Figure 11A shows that both cp45 and JS strains have a similar preference for the 2 \rightarrow 3 linkage. Figure 11B shows that cp45 has a preference for the 2 \rightarrow 6 linkage relative to the JS strains. Comparison of Figures 11A and 11B shows that cp45 has a greater preference for the 2 \rightarrow 3 linkage than for the 2 \rightarrow 6 linkage.

Example 11: Neuraminidase Inhibition Assays for Comparison of cp45 and HPIV-3 (JS) Antigenic Sites

The antigenic relatedness of the neuraminidase active site of cp45 and the parent JS strain of the virus was compared using neuraminidase inhibitory antibodies. A monospecific rabbit antiserum to affinity purified HPIV-3 HN glycoprotein and three monoclonal antibodies to the HN glycoprotein, 2-14-1, 13-9-6-2 and 170/8, were used in the neuraminidase inhibition assay. These antibodies are known to recognize neuraminidase active sites of the prototype HPIV-3 (47885) strain. The antibodies were tested at two-fold serial dilutions for each virus strain and the results were compared with the linear slopes of the reactivity pattern. A Mab 3-8-1 exclusively inhibiting the HA of the virus was used as a negative control, but did not show an inhibitory role of the neuraminidase activity (data not shown). Figure 12A shows that no significant difference in antigenic sites between cp45 and HPIV-3 (JS) was observed for any of the inhibiting antibodies or antisera between cp45 and JS

strains when fetuin was used as the assay substrate. Figure 12B shows that the neuraminidase activity of the cp45 strain was less inhibited than the activity of the JS strain by the monoclonal antibodies 12-9-6-2 and 170/8 5 when the relatively smaller neuraminlactose substrate was used as the assay substrate. However, the extent of inhibition of the two strains was similar for the monoclonal antibody 2-14-1 and for the monospecific rabbit antisera.

10

In light of the detailed description of the invention and the examples presented above, it can be appreciated that the several objects of the invention are achieved. The explanations and illustrations presented 15 herein are intended to acquaint others skilled in the art with the invention, its principles, and its practical application. Those skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use. 20 Accordingly, the specific embodiments of the present invention as set forth are not intended as being exhaustive or limiting of the invention.

BIBLIOGRAPHY

Anderson, et al. 1992. Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: Amino acid substitutions affecting folding, transport and cleavage. *J. Gen. Virol.* 73(Pt. 5):1177-88.

Belshe and Hissom 1982. Cold adaptation of parainfluenza virus type induction of three phenotypic markers. *J. Med. Virol.* 10:235-242.

Belshe, et al. 1992. Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. *J. Clin. Microbiol.* 30:2064-2070

Baybutt and Pringle 1987. Molecular cloning and sequencing of the F and 22K membrane protein genes of the RSS-2 strain of respiratory syncytial virus. *J. Gen. Virol.* 68 (Pt 11):2789-96.

Clements, et al. 1991. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. *J. Clin. Microbiol.* 29:1175-1182.

Collins, et al. 1993. Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA. *Virol.* 195(1):252-6.

Crookshanks-Newman and Belshe. 1986. Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3. *J. Med. Virol.* 18:131-137.

Galinski et al. 1986. Molecular cloning and sequence analysis of the human parainfluenza 3 virus RNA encoding the nucleocapsid protein. *Virol.* 149:139-151.

Galinski et al. 1986'. Molecular cloning and sequence analysis of the human parainfluenza 3 virus mRNA encoding the P and C proteins. *Virol.* 154:46-60.

5 Galinski et al. 1988. Molecular cloning and sequence analysis of the human parainfluenza 3 virus gene encoding the L protein. *Virol.* 165:499-510.

Hall et al. 1993. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees. *J. Infect. Dis.* 167:958-962.

10 Hu, et al. 1990. Molecular cloning and sequence analysis of the fusion glycoprotein gene of human parainfluenza virus type 2. *Virol.* 179(2):915-20.

15 Johnson and Collins 1988. The A and B subgroups of human respiratory syncytial virus: Comparison of intergenic and gene-overlap sequences. *J. Gen. Virol.* 69(Pt 11):2901-6.

Johnson and Collins 1988'. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: Sequence conservation provides a structural basis for 20 antigenic relatedness. *J. Gen. Virol.* 69(Pt 10):2623-8.

Kawano, et al. 1990. Sequence determination of the hemagglutinin-neuraminidase (HN) gene of human parainfluenza type 2 virus and the construction of a phylogenetic tree for HN proteins of all the 25 paramyxoviruses that are infectious to humans. *Virol.* 174(1):303-13.

Kawano, et al. 1990'. Sequence of the fusion protein gene of human parainfluenza type 2 virus and its 3'

intergenic region: Lack of small hydrophobic (SH) gene. Virol. 178(1):289-92.

Kuppuswamy, et al. 1991. Single nucleotide primer extension to detect genetic diseases: Experimental

5 application to hemophilia B (factor IX) and cystic fibrosis genes. Proc. Natl. Acad. Sci. USA. 88:1143-1147

Lawson et al. 1995. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA 92:4477-4481.

10 Lerch, et al. 1990. Nucleotide sequence analysis and expression from recombinant vectors demonstrates that the attachment protein G of bovine respiratory syncytial virus is distinct from that of human respiratory syncytial virus. J. Virol. 64(11):5559-69.

Lopez, et al. 1988. Nucleotide sequence of the fusion and phosphoprotein genes of human respiratory syncytial (RS) virus long strain: Evidence of subtype genetic heterogeneity. Virus Research. 10(2-3):249-61.

20 Martin-Gallardo, et al. 1991. Expression of the F glycoprotein gene from human respiratory syncytial virus in Escherichia coli: Mapping of a fusion inhibiting epitope. Virol. 184(1):428-32.

Martin-Gallardo, et al. 1993. Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J. Gen. Virol. 74(Pt.3):453-8.

Matsuoka, et al. 1990. Sequence of the hemagglutinin-neuraminidase gene of human parainfluenza virus type 1. Virus Research. 16(1):107-13.

Merson, et al. 1988. Molecular cloning and sequence determination of the fusion protein gene of human parainfluenza virus type 1. *Virol.* 167(1):97-105

5 Palese, P. 1995. Genetic engineering of infectious negative-strand RNA viruses. [Review]. *Trends in Microbiology.* 3(4):123-5.

Precious, et al. 1990. Sequence analysis of the HN gene of parainfluenza virus type 2. *J. Gen. Virol.* 71(Pt 5):1163-8.

10 Schnell et al. 1994. Infectious rabies viruses from clone cDNA. *EMBO J.* 13:4195-4203.

15 Spriggs and Collins 1986. Human parainfluenza virus type 3: messenger RNAs, polypeptide coding assignments, intergenic sequences, and genetic map. *J. Virol.* 59:646-654.

Spriggs and Collins 1986. Sequence analysis of the P and C protein genes of human parainfluenza virus type 3: Patterns of amino acid sequence homology among paramyxovirus proteins. *J. Gen. Virol.* 67:2705-2719.

20 Stokes, et al. 1993. The complete nucleotide sequence of two-cold adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3). *Virus Res.* 30:43-52.

25 Storey, et al. 1984. Structural characterization of viron proteins and genomic RNA of human parainfluenza virus 3. *J. Virol.* 52:761-766.

Sullender, et al. 1990. The respiratory syncytial virus subgroup B attachment glycoprotein: Analysis of sequence, expression from a recombinant vector, and evaluation as an immunogen against homologous and 5 heterologous subgroup virus challenge. *Virol.* 178(1):195-203.

Sullender, et al. 1991. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. *J. Virol.* 65(10):5425-34.

10 Walravens, et al. 1990. Sequence comparison between the fusion protein of human and bovine respiratory syncytial viruses. *J. Gen. Virol.* 71 (Pt 12):3009-14.

WHAT IS CLAIMED IS:

1. An enveloped, negative-sense, single-stranded RNA hybrid virus, the hybrid virus having a genome comprising, operatively linked for expression, (i) a nucleic acid sequence which encodes at least one surface antigen of a target virus, the surface antigen being different from surface antigens of the HPIV-3 strain designated as cp45 and (ii) a nucleic acid sequence which encodes a variant large protein, L, the variant L protein being a HPIV-3 L protein having at least one variation in amino acid sequence relative to its wild-type HPIV-3 L protein.
5
10
2. The hybrid virus of claim 1 wherein the variant L protein has an amino acid sequence having at least about a 90% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and the variant L protein has RNA-polymerase activity which is less than the polymerase activity normally associated with the target virus at a temperature of about 39°C.
5
3. The hybrid virus of claim 1 wherein the hybrid virus has a genome comprising (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of cp45; (ii) a nucleic acid sequence which encodes the nucleocapsid protein, NP, of cp45; (iii) a nucleic acid sequence which encodes the phosphoprotein, P[+C], of cp45; (iv) a nucleic acid sequence which encodes the matrix protein, M, of cp45; (v) a nucleic acid sequence which encodes at least one surface antigen of a target virus, the surface antigen being different from surface antigens of cp45; and (vi) a nucleic acid sequence which encodes a variant large protein, L, having at least about a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein,
5
10

15 having at least two substitutions in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein and having RNA-polymerase activity which is less than the polymerase activity normally associated with the target virus at a temperature of about 39°C.

4. A live vaccine suitable for use against a target virus, the vaccine comprising the hybrid virus of claim 2 and a pharmaceutically appropriate carrier.

5. The vaccine of claim 4 wherein the amino acid sequence of the variant L protein has at least about a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein.

6. The vaccine of claim 4 wherein the amino acid sequence of the variant L protein has at least about a 99.5% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein.

7. The vaccine of claim 4 wherein the variant L protein has at least one substitution in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the substitution being selected from the group consisting of His for Tyr at residue 942, Phe for Leu at residue 992 and Ile for Thr at residue 1558.

8. The vaccine of claim 4 wherein the variant L protein has at least two substitutions in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the substitutions being His for Tyr at residue 942 and Phe for Leu at residue 992.

9. The vaccine of claim 4 wherein the variant L protein is the cp45 L protein.

10. The vaccine of claim 4 wherein the target virus is an enveloped, negative-sense, single-stranded RNA virus.

11. The vaccine of claim 4 wherein the target virus is selected from the group consisting of HPIV-1, HPIV-2 and RSV.

12. The vaccine of claim 4 wherein the variant L protein is an RNA-dependent RNA polymerase having an activity which is at least about 10% less than the activity of the wild-type HPIV-3 (JS) polymerase.

13. The vaccine of claim 4 wherein the genome of the virus further comprises: (i) a nucleic acid sequence which encodes the nucleocapsid protein, NP, of a HPIV-3 virus and (ii) a nucleic acid sequence which encodes the phosphoprotein, P[+C], of a HPIV-3 virus.

14. The vaccine of claim 4 wherein the genome of the virus further comprises: (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of a HPIV-3 virus; (ii) a nucleic acid sequence which encodes the nucleocapsid protein, NP, of a HPIV-3 virus; (iii) a nucleic acid sequence which encodes the phosphoprotein, P[+C], of a HPIV-3 virus; and (iv) a nucleic acid sequence which encodes the matrix protein, M, of a HPIV-3 virus.

15. The vaccine of claim 14 wherein the 3' leader region of the HPIV-3 genome is the 3' leader region of the cp45 genome.

16. The vaccine of claim 14 wherein the HPIV-3 phosphoprotein is the phosphoprotein of cp45.

17. The vaccine of claim 14 wherein the HPIV-3 matrix protein is the matrix protein of cp45.

18. The vaccine of claim 14 wherein the 3' leader region of the HPIV-3 genome is the 3' leader region of the cp45 genome and the HPIV-3 NP, P[+C], and M proteins are cp45 NP, P[+C] and M proteins.

19. The vaccine of claim 4 wherein the genome of the hybrid virus comprises (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of cp45; (ii) a nucleic acid sequence which 5 encodes the nucleocapsid protein, NP, of cp45; (iii) a nucleic acid sequence which encodes the phosphoprotein, P[+C], of cp45; (iv) a nucleic acid sequence which encodes the matrix protein, M, of cp45; (v) a nucleic acid sequence which encodes at least one surface antigen 10 of a target virus selected from the group consisting of HPIV-1, HPIV-2 and RSV; and (vi) a nucleic acid sequence which encodes a variant large protein, L, having RNA-polymerase activity which is less than the polymerase activity normally associated with the target virus at a 15 temperature of about 39°C, having at least about a 99.8% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and having at least two substitutions in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the substitutions being 20 His for Tyr at residue 942 and Phe for Leu at residue 992.

20. A plasmid vector comprising a positive or negative sense genome which includes, operatively linked for expression, (i) a nucleic acid sequence which encodes the surface antigens of a target virus, the surface 5 antigens being different from surface antigens of the HPIV-3 strain designated as cp45, and (ii) a nucleic acid

sequence which encodes a variant large protein, L, having an amino acid sequence which has at least about a 90% sequence identity with the amino acid sequence of the 10 wild-type HPIV-3 (JS) L protein and which has at least one variation in amino acid sequence relative to the L protein of wild-type HPIV-3 (JS), the variant L protein having an RNA-polymerase activity which is less than the polymerase activity normally associated with the target 15 virus at a temperature of about 39°C.

21. A host cell transfected with the plasmid vector set forth in claim 20.

22. A method for producing an enveloped, negative-sense, single-stranded RNA hybrid virus suitable for use as a live vaccine, the method comprising:

5 preparing the chimeric plasmid vector of claim 20, transfecting a host cell with the chimeric plasmid vector,

cotransfected the host cell with plasmid vectors that express wild-type HPIV-3 NP, P and L proteins;

10 incubating the transfected host cell to produce a hybrid virus; and

isolating the hybrid virus in a pharmaceutically acceptable medium.

23. The method as set forth in claim 22 wherein the chimeric plasmid vector is prepared by

5 preparing a cDNA clone of the genome of the HPIV-3 strain designated as cp45, the genome comprising a nucleic acid sequence which encodes the HN protein of cp45 and the L protein of cp45,

incorporating the cDNA clone of the cp45 genome into a plasmid vector,

10 preparing a cDNA clone of or obtaining DNA of the genome of a target virus, the genome comprising a nucleic

acid sequence which encodes the surface antigens of the target virus, and

15 replacing the region of the plasmid vector's genome which encodes the HN protein of cp45 with the nucleic acid sequence which encodes the surface antigens of the target virus.

24. The method as set forth in claim 22 wherein the amino acid sequence of the variant L protein has at least about a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and has 5 at least two substitutions in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the substitutions being selected from the group consisting of His for Tyr at residue 942 and Phe for Leu at residue 992.

25. The method as set forth in claim 22 wherein the genome further includes (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of cp45, (ii) a nucleic acid sequence which 5 encodes the nucleocapsid protein, NP, of cp45, (iii) a nucleic acid sequence which encodes the phosphoprotein, P [+C], of cp45, (iv) a nucleic acid sequence which encodes the matrix protein, M, of cp45.

26. An enveloped, negative-sense, single-stranded RNA hybrid virus, the hybrid virus having a genome comprising, operatively linked for expression, a nucleic acid sequence which encodes (i) at least one surface 5 antigen of a target virus, the surface antigen being different from surface antigens of the HPIV-3 strain designated as cp45 and (ii) a portion of the cp45 HN protein, the encoded portion having a neuraminidase activity and including an amino acid sequence which is

10 the same as the amino acid sequence from residue 160 to residue 385 of the HN protein of cp45.

27. A live vaccine suitable for use against a target virus, the vaccine comprising the hybrid virus of claim 26 and a pharmaceutically appropriate carrier.

28. The vaccine as set forth in claim 27 wherein the viral genome further comprises a nucleic acid sequence which encodes a variant large protein, L, having an amino acid sequence which has at least about a 90% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and which has at least one variation in amino acid sequence relative to the L protein of wild-type HPIV-3 (JS), the variant L protein having an RNA-polymerase activity which is less than the polymerase activity normally associated with the target virus at a temperature of about 39°C.

29. The vaccine as set forth in claim 28 wherein the amino acid sequence of the variant L protein has at least about a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and has at least one substitution in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the substitution being selected from the group consisting of His for Tyr at residue 942, Phe for Leu at residue 992 and Ile for Thr at residue 1558.

30. The vaccine as set forth in claim 28 wherein the amino acid sequence of the variant L protein has at least about a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and has at least two substitutions in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the

substitutions being His for Tyr at residue 942 and Phe for Leu at residue 992.

31. The vaccine as set forth in claim 27 wherein the viral genome further comprises a nucleic acid sequence which encodes the large protein, L, of cp45.

32. An enveloped, negative-sense, single-stranded RNA hybrid virus having a genome comprising, operatively linked for expression, (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of a wild-type HPIV-3 target virus or which encodes at least one protein selected from the group consisting of the matrix protein, M, of the target virus, the fusion protein, F, of the target virus and the hemagglutinin-neuraminidase protein, HN, of the target virus, and (ii) a nucleic acid sequence which encodes a variant HPIV-3 large protein, L, having an amino acid sequence which has at least one variation in amino acid sequence relative to the L protein of the target virus, the variant L protein having RNA-polymerase activity which is less than the RNA-polymerase activity normally associated with the L protein of the target virus at a temperature of about 39°C.

33. A live vaccine suitable for use against a HPIV-3 target virus, the vaccine comprising the hybrid virus of claim 32 and a pharmaceutically appropriate carrier.

34. The vaccine of claim 33 wherein the amino acid sequence of the variant L protein has at least about a 90% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and has at least one variation in amino acid sequence relative to the L protein of the wild-type HPIV-3 (JS) virus.

35. The vaccine of claim 33 wherein the amino acid sequence of the variant L protein has at least about a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and has at least one 5 variation in amino acid sequence relative to the L protein of the wild-type HPIV-3 (JS) virus.

36. The vaccine of claim 33 wherein the amino acid sequence of the variant L protein has at least about a 99.5% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and has at least one 5 variation in amino acid sequence relative to the L protein of the wild-type HPIV-3 (JS) virus.

37. The vaccine of claim 33 wherein the amino acid sequence of the variant L protein has at least about a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and has at least one 5 substitution in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the substitution being selected from the group consisting of His for Tyr at residue 942, Phe for Leu at residue 992 and Ile for Thr at residue 1558.

38. The vaccine of claim 33 wherein the amino acid sequence of the variant L protein has at least about a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and has at least two 5 substitutions in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the substitutions being His for Tyr at residue 942 and Phe for Leu at residue 992.

39. The vaccine of claim 33 wherein the variant L protein is the L protein of the HPIV-3 strain designated as cp45.

40. The vaccine of claim 33 wherein the viral genome further comprises a nucleic acid sequence which encodes a variant hemagglutinin-neuraminidase protein, HN, having an amino acid sequence which has at least 5 about a 90% sequence identity with the amino acid sequence of the HN protein of wild-type HPIV-3 (JS) virus, which has at least one variation in amino acid sequence relative to the HN protein of the target virus and which has at least one variation in amino acid 10 sequence relative to the HN protein of the HPIV-3 (JS) virus, the variation relative to the HN protein of HPIV-3 (JS) being at or within about five amino acid residues of residue 384, the variant HN protein having neuraminidase activity which is less than the neuraminidase activity 15 normally associated with the HN protein of the target virus.

41. The vaccine of claim 40 wherein the amino acid sequence of the variant HN protein has a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) HN protein.

42. The vaccine of claim 40 wherein the amino acid sequence of the variant HN protein has a 99.5% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) HN protein.

43. The vaccine of claim 40 wherein the variant HN protein has at least one substitution in amino acid sequence relative to the wild-type HPIV-3 (JS) HN protein, the substitution being Val for Ala at residue 5 384.

44. The vaccine of claim 33 wherein the viral genome further comprises a nucleic acid sequence which

encodes the hemagglutinin-neuraminidase protein, HN, of the HPIV-3 strain designated as cp45.

45. The vaccine of claim 33 wherein the viral genome further comprises a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of the HPIV-3 strain designated as cp45 or which 5 encodes a protein selected from the group consisting of the nucleocapsid protein, NP, of cp45, the phosphoprotein, P[+C], of cp45, the matrix protein, M, of cp45, and the fusion protein, F, of cp45.

46. The vaccine of claim 33 wherein the viral genome further comprises a nucleic acid sequence which encodes the hemagglutinin-neuraminidase protein, HN, of the wild-type HPIV-3 target virus.

47. The vaccine of claim 33 wherein the viral genome comprises (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of cp45, (ii) a nucleic acid sequence which encodes the 5 nucleocapsid protein, NP, of cp45, (iii) a nucleic acid sequence which encodes the phosphoprotein, P[+C], of cp45, (iv) a nucleic acid sequence which encodes the matrix protein, M, of cp45, (v) a nucleic acid sequence which encodes the fusion protein, F, of cp45, (vi) a 10 nucleic acid sequence which encodes the hemagglutinin-neuraminidase protein, HN, of the wild-type HPIV-3 target virus, and (vii) a nucleic acid sequence which encodes the L protein of cp45.

48. The vaccine of claim 33 wherein the hemagglutinin-neuraminidase protein encoded by the viral genome is the hemagglutinin-neuraminidase protein, HN, of wild-type HPIV-3 (JS).

49. The vaccine of claim 33 wherein the viral genome comprises (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of the target virus, (ii) a nucleic acid sequence which encodes the nucleocapsid protein, NP, of the target virus, (iii) a nucleic acid sequence which encodes the phosphoprotein, P{+C}, of the target virus, (iv) a nucleic acid sequence which encodes the matrix protein, M, of the target virus, (v) a nucleic acid sequence which encodes the fusion protein, F, of the target virus, (vi) a nucleic acid sequence which encodes the hemagglutinin-neuraminidase protein, HN, of the target virus, and (vii) a nucleic acid sequence which encodes the variant L protein.

50. An enveloped, negative-sense, single-stranded RNA hybrid virus having a genome comprising, operatively linked for expression, (i) a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of a wild-type HPIV-3 target virus or which encodes at least one protein selected from the group consisting of the matrix protein, M, of the target virus, the fusion protein, F, of the target virus and the large protein, L, of the target virus, and (ii) a nucleic acid sequence which encodes a variant hemagglutinin-neuraminidase protein, HN, having an amino acid sequence which has at least about a 90% sequence identity with the amino acid sequence of the HN protein of wild-type HPIV-3 (JS) virus, which has at least one variation in amino acid sequence relative to the HN protein of the target virus and which has at least one variation in amino acid sequence relative to the HN protein of the HPIV-3 (JS) virus, the variation relative to the HN protein of HPIV-3 (JS) being at or within about five amino acid residues of residue 384, the variant HN protein having neuraminidase activity which is less than the neuraminidase activity

normally associated with the HN protein of the target virus.

51. A live vaccine suitable for use against a HPIV-3 target virus, the vaccine comprising the hybrid virus of claim 50 and a pharmaceutically appropriate carrier.

52. The vaccine of claim 51 wherein the amino acid sequence of the variant HN protein has a 99% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) HN protein.

53. The vaccine of claim 51 wherein the amino acid sequence of the variant HN protein has a 99.5% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) HN protein.

54. The vaccine of claim 51 wherein the variant HN protein has at least one substitution in amino acid sequence relative to the wild-type HPIV-3 (JS) HN protein, the substitution being Val for Ala at residue 384.

55. The vaccine of claim 51 wherein the variant HN protein is the HN protein of the HPIV-3 strain designated as cp45.

56. The vaccine of claim 51 wherein the viral genome further comprises a nucleic acid sequence which encodes a variant large protein, L, having an amino acid sequence which has at least about a 90% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and which has at least one substitution in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the substitution being selected from the group consisting of His for Tyr at residue 942, Phe for Leu at

10 residue 992 and Ile for Thr at residue 1558, the variant L protein having an RNA-polymerase activity which is less than the RNA-polymerase activity normally associated with the L protein of the target virus at a temperature of about 39°C.

57. The vaccine of claim 51 wherein the viral genome further comprises a nucleic acid sequence which encodes a variant large protein, L, having an amino acid sequence which has at least about a 90% sequence identity with the amino acid sequence of the wild-type HPIV-3 (JS) L protein and which has at least two substitutions in amino acid sequence relative to the wild-type HPIV-3 (JS) L protein, the substitutions being His for Tyr at residue 942 and Phe for Ile at residue 992, the variant L protein 10 having an RNA-polymerase activity which is less than the RNA-polymerase activity normally associated with the L protein of the target virus at a temperature of about 39°C.

58. The vaccine of claim 51 wherein the viral genome further comprises a nucleic acid sequence which encodes the large protein, L, of cp45.

59. The vaccine of claim 51 wherein the viral genome further comprises a nucleic acid sequence which is the same as the nucleic acid sequence of the 3' leader region of cp45 or which encodes a protein selected from 5 the group consisting of the nucleocapsid protein, NP, of cp45, the phosphoprotein, P[+C], of cp45, the matrix protein, M, of cp45, and the fusion protein, F, of cp45.

60. A method for determining whether a HPIV-3 virus or a cp45-hybrid virus is attenuated, the method comprising confirming the presence of at least one variation in the genome of the virus relative to the

5 genome of wild-type HPIV-3, the variation being in the gene which encodes the L protein or in the gene which encodes the HN protein.

61. The method of claim 60 wherein the presence of at least one variation in the gene encoding the L protein of the virus is confirmed by performing a complementation assay, wherein the virus is complemented in a host cell 5 with L protein of the wild-type HPIV-3 virus.

62. A method for determining whether a HPIV-3 or a cp45-hybrid virus has a temperature sensitive phenotype, the method comprising

obtaining a sample of a HPIV-3 virus or a cp45-5 hybrid virus,

performing a first plaque assay on the virus as a control assay;

transfecting a mammalian host cell with a plasmid vector that expresses L protein of wild-type HPIV-3 (JS);

10 infecting the host cell with the virus;

incubating to yield a complemented virus;

performing a second plaque assay on the complemented viral sample; and

15 comparing the second plaque assay to the control assay to confirm the presence of the temperature sensitive phenotype.

63. The method of claim 62 further comprising cotransfected the host cell with a plasmid vector that expresses P protein of wild-type HPIV-3 (JS).

64. The method of claim 62 further comprising cotransfected the host cell with a plasmid vector that expresses NP protein of wild-type HPIV-3 (JS).

LEADER



F/G/

		Nucleotide		Amino Acid	
		Location	Change	Location	Change (wt. \Rightarrow cp45)
		23	T \Rightarrow C		
		24	C \Rightarrow T		
		28	G \Rightarrow T		
NP					
P		334	TCC \Rightarrow TCT	85	
		376	AAU \Rightarrow AAC	99	
M		627	CCC \Rightarrow ACC	199	Pro \Rightarrow Thr
P		658	AAC \Rightarrow AAT	155	
		1451	ATA \Rightarrow GTA	420	Ile \Rightarrow Val
		1541	GCA \Rightarrow ACA	450	Ala \Rightarrow Thr
		115	GGT \Rightarrow GGC	14	
HJ		1224	GCT \Rightarrow GCT	384	
		700	TAT \Rightarrow TAC	226	
		1348	GAA \Rightarrow GAC	442	
I		2698	TCA \Rightarrow TCG	892	
		2846	TAC \Rightarrow CAC	942	Tyr \Rightarrow His
		2998	TTC \Rightarrow TTT	992	Leu \Rightarrow Phe
		3958	TTC \Rightarrow TTT	1312	
		4695	ACT \Rightarrow ATT	1558	Thr \Rightarrow Ile

TRAILER

3 / 16

FIG. 3B



2 / 16

FIG. 2A
1 2 3

FIG. 2B

Cycles	Phosphor- imager Analysis	cp45	wt	Phosphor- imager Analysis
5	490			694
10		524		859
15		608		3566
20		3866		20566
25		14483		29249

→ 559bp




FIG. 4A

4 / 16





FIG. 4B



5 / 16

FIG. 5A





FIG. 5B



6 / 16

FIG. 6A



FIG. 6B



FIG. 6C





FIG. 6D




7 / 16

FIG. 7A



8 / 16

FIG. 7B



9 / 16

FIG.8A




FIG.8B




FIG.8C





FIG.8D



10 / 16

FIG. 9A




FIG. 9B





FIG. 9C




FIG. 9D




11 / 16

FIG. 10A




12 / 16

FIG. 10B




13 / 16

Fig. 11A




14 / 16

E/G. 1/8




15 / 16

FIG. 12A



16 / 16

FIG. 12B



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/19512

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL : 424/93.1, 93.2; 93.21; 435/235.1, 240.1, 320.1; 536/22.1, 23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.1, 93.2, 93.21; 435/235.1, 240.1, 320.1; 536/22.1, 23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BOISIS, APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A 5,169,628 (WATHEN) 08 December 1992, see entire document.	1-59
Y	BELSHE, R. B. et al. Evaluation of a Live Attenuated, Cold-Adapted Parainfluenza Virus Type 3 Vaccine in Children. Journal of Clinical Microbiology. August 1992, Vol. 30, No. 8, pages 2064-2070, see entire document.	1-64
Y	STOKES, A. et al. The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3). Virus Research. 1993, Vol. 30, pages 43-52, see entire document.	1-64

Further documents are listed in the continuation of Box C.



See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

30 JANUARY 1997

Date of mailing of the international search report

25 FEB 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faximile No. (703) 305-3230

Authorized officer

ERNEST JONES

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

In. .ational application No.

PCT/US96/19512

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BELSHE, R. B. et al. Cold Adaption of Parainfluenza Virus Type 3: Induction of Three Phenotypic Markers. Journal of Medical Virology. 1982, Vol. 10, pages 235-242, see entire document.	1-64

INTERNATIONAL SEARCH REPORT

I. International application No.
PCT/US96/19512

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A01N 63/00, 65/00; C12N 7/00, 7/01, 5/00, 5/02, 15/00, 15/09, 15/63, 15/70, 15/74; C07H 19/00, 21/00, 21/02, 21/04

THIS PAGE BLANK (USPTO)